NIR-II Fluorescence Imaging Protocols: A Complete Guide to Deep-Tissue Biomarker Detection

Abstract

This comprehensive guide provides researchers and drug development professionals with a detailed protocol framework for using near-infrared window II (NIR-II, 1000-1700 nm) fluorescent probes to detect biomarkers in deep tissues. The article explores the foundational principles of NIR-II imaging, presents step-by-step methodologies for probe synthesis, administration, and in vivo imaging, addresses common troubleshooting and optimization challenges, and establishes validation benchmarks for comparing probe performance. The content synthesizes the latest advances to enable reliable, high-contrast visualization of molecular targets through scattering biological tissue, supporting applications from preclinical research to translational medicine.

Beyond the Visible: Understanding NIR-II Physics and Probe Design for Deep Tissue Penetration

The second near-infrared (NIR-II) window, spanning 1000-1700 nm, offers transformative advantages for deep-tissue in vivo fluorescence imaging. The core principles enabling this superior performance are reduced scattering and minimized autofluorescence.

• Reduced Light Scattering: In biological tissue, light scattering is primarily caused by spatial variations in refractive index. The scattering coefficient (μs') follows an approximate inverse power-law relationship with wavelength (λ), often modeled as μs' ∝ λ^(-b), where b is the scattering power (typically ~1-2 for tissue). As wavelength increases into the NIR-II region, scattering decreases dramatically. This reduction allows photons to travel more ballistically, maintaining focus and enabling higher-resolution imaging at greater depths.
• Minimized Autofluorescence: Endogenous fluorophores (e.g., flavins, collagen, porphyrins) require excitation by higher-energy photons. Their excitation and emission profiles predominantly reside in the visible and first NIR window (NIR-I, 700-900 nm). In the NIR-II region, this intrinsic background fluorescence is negligible, leading to a dramatically improved signal-to-background ratio (SBR).

These principles collectively permit deeper penetration (often >5 mm), superior spatial resolution (down to ~10-30 μm at depth), and high-fidelity visualization of anatomical and molecular features in vivo.

Table 1: Optical Properties of Biological Tissue Across Spectral Windows

Parameter	Visible (400-700 nm)	NIR-I (700-900 nm)	NIR-II (1000-1700 nm)	Source / Notes
Avg. Scattering Coefficient (μs')	~100-200 cm⁻¹	~20-50 cm⁻¹	~5-15 cm⁻¹	Measured in brain/muscle; decreases as λ increases.
Absorption by Hemoglobin	Very High (ε > 10⁵ M⁻¹cm⁻¹)	Moderate-High	Very Low	Oxy-/deoxy-hemoglobin absorption minima >1000 nm.
Absorption by Water	Very Low	Low	Increases significantly >1150 nm	Limits long-wavelength end of NIR-II (~1500-1700 nm).
Typical Autofluorescence	Very High	Moderate	Negligible	Enables SBR >10x higher than NIR-I.
Optimal Penetration Depth	<1 mm	1-3 mm	3-8 mm (up to ~2 cm in some reports)	Depth for useful microscopic/mesoscopic imaging.
Achievable Resolution at Depth	Poor	~50-200 μm	~10-50 μm	Due to reduced scattering.

Table 2: Comparison of Fluorescent Imaging Windows

Imaging Window	Wavelength Range (nm)	Key Advantages	Primary Limitations
NIR-I	700-900	Established dyes & instruments.	Significant scattering, moderate autofluorescence.
NIR-IIa	1300-1400	Very low scattering & autofluorescence.	Requires InGaAs detectors, limited probe library.
NIR-IIb	1500-1700	Lowest scattering.	Water absorption increases, requires specialized optics.

Key Experimental Protocols

Protocol 1: Measuring Signal-to-Background Ratio (SBR) for NIR-II ProbesIn Vivo

Objective: To quantitatively compare the in vivo performance of an NIR-II fluorescent probe against an NIR-I probe.

Materials: See "The Scientist's Toolkit" below.

Methodology:

• Animal Model Preparation: Anesthetize a mouse (e.g., nude or C57BL/6) and place it on a heated stage in the imaging system. Maintain body temperature at 37°C.
• Pre-injection Imaging: Acquire a baseline image in both the NIR-I (e.g., 800 nm emission filter) and NIR-II (e.g., 1300 nm long-pass filter) channels using identical laser excitation (e.g., 808 nm). Use the same acquisition time and laser power.
• Probe Administration: Intravenously inject the NIR-II probe (e.g., 100 µL of 100 µM IRDye 1064) via the tail vein. For comparison, in a separate cohort, inject a standard NIR-I probe (e.g., ICG).
• Time-Course Imaging: Acquire images at regular intervals (e.g., 1, 5, 15, 30, 60 min post-injection) in both spectral channels.
• Image Analysis:
  • Region of Interest (ROI) Selection: Draw an ROI over a major organ (e.g., liver) or target tumor.
  • Background ROI Selection: Draw an ROI over adjacent muscle or non-target tissue.
  • Calculation: Calculate SBR = (Mean Signal Intensity in Target ROI) / (Mean Signal Intensity in Background ROI). Plot SBR vs. time for both probes.
  • Penetration Depth Assessment: Using the NIR-II image at peak SBR, measure the Full Width at Half Maximum (FWHM) of a line profile across a deep vessel or tumor boundary to estimate resolution.

Protocol 2: Phantom-Based Scattering and Absorption Measurement

Objective: To experimentally validate reduced scattering in the NIR-II window using tissue-mimicking phantoms.

Methodology:

• Phantom Preparation: Prepare 1% agarose in PBS. For scattering phantoms, add varying concentrations (0.5%, 1.0%, 2.0%) of lipid emulsion (Intralipid). For absorption phantoms, add varying concentrations of India ink. Pour into slab cuvettes.
• System Setup: Use a spectrophotometer with an integrating sphere attachment capable of measurements up to 1700 nm.
• Measurement: Place each phantom in the spectrophotometer. Measure the total transmittance (Tt) and diffuse reflectance (Rd) spectra from 600 nm to 1600 nm.
• Data Fitting: Use the inverse adding-doubling (IAD) method or other light transport models to fit the measured Tt and Rd spectra and extract the reduced scattering coefficient (μs') and absorption coefficient (μa) as a function of wavelength.
• Validation: Confirm that μs' for all phantoms decreases with a power-law dependence on wavelength. Plot μs' vs. λ on a log-log scale and compare the slope to theoretical values.

Visualization of Principles and Workflows

Diagram Title: Principle of Reduced Scattering with Wavelength

Diagram Title: In Vivo NIR-II Probe Evaluation Protocol

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for NIR-II Deep-Tissue Imaging Research

Item	Function & Relevance	Example Product / Note
NIR-II Fluorescent Probes	Emit in the 1000-1700 nm range; the core agent for imaging.	Organic Dyes: CH1055, IR-1061. Inorganic: Rare-earth-doped nanoparticles (NaYF₄:Yb,Er,Nd), Quantum Dots (PbS/CdS). Single-Walled Carbon Nanotubes (SWCNTs).
NIR-I Reference Dye	Control for comparative studies in the first window.	Indocyanine Green (ICG), IRDye 800CW.
808 nm or 980 nm Laser	Common excitation sources for NIR fluorophores.	Diode lasers. 808 nm minimizes water heating. 980 nm excites Yb³⁺ sensitizers.
InGaAs Camera	Detects photons in the 900-1700 nm range. Essential for NIR-II.	Cooled, 2D array cameras (e.g., from Princeton Instruments, Hamamatsu).
Spectrophotometer with NIR Detector	Measures absorption/emission spectra of probes up to 1700 nm.	Requires extended InGaAs or cooled PbS detectors.
Tissue-Mimicking Phantoms	Calibrate systems & model light transport.	Agarose with Intralipid (scatterer) & India ink (absorber).
Animal Model	In vivo testing of probe biodistribution and targeting.	Nude mice for xenografts; transgenic for disease models.
Image Analysis Software	Quantifies signal intensity, SBR, resolution, and kinetics.	ImageJ (FIJI), Living Image (PerkinElmer), MATLAB.
Long-Pass Emission Filters	Block excitation laser light and NIR-I emission.	1100 nm, 1250 nm, or 1300 nm long-pass filters.

This document provides detailed application notes and protocols for three core NIR-II fluorescent probe architectures, framed within a thesis focused on advancing protocols for deep tissue biomarker detection. The development of robust probes operating in the second near-infrared window (NIR-II, 1000-1700 nm) is critical for achieving high-resolution, deep-tissue imaging with minimal autofluorescence and scattering. These protocols are designed for researchers and drug development professionals engineering probes for in vivo targeting, sensing, and imaging.

Organic Dye-Based NIR-II Probes

Application Notes: Organic small-molecule dyes, such as those based on donor-acceptor-donor (D-A-D) structures, offer tunable emission, relatively rapid clearance, and potential for chemical modification for biomolecular targeting. Key challenges include moderate quantum yield (QY) in aqueous media and potential photobleaching.

Protocol 1.1: Conjugation of a NIR-II Dye to a Targeting Antibody

• Objective: To create a targeted NIR-II imaging probe by covalently linking a carboxylic acid-functionalized organic dye (e.g., CH1055 derivative) to a monoclonal antibody.

• Materials:

  • NIR-II dye-NHS ester (or dye-COOH for activation)
  • Targeting monoclonal antibody (e.g., anti-EGFR)
  • Anhydrous DMSO
  • ​0.1 M Sodium Bicarbonate Buffer (pH 8.3)
  • PD-10 Desalting Column (Sephadex G-25)
  • Phosphate Buffered Saline (PBS, pH 7.4)
  • Centrifugal filter unit (30 kDa MWCO)

• Procedure:

  • Dye Preparation: Dissolve the NIR-II dye-NHS ester in anhydrous DMSO to a concentration of 5 mM. If using a carboxylic acid, activate with EDC/NHS in DMSO for 30 minutes prior to reaction.
  • Antibody Preparation: Buffer-exchange the antibody into 0.1 M sodium bicarbonate buffer (pH 8.3) using a PD-10 column to a final concentration of 2 mg/mL.
  • Conjugation: Slowly add the dye solution to the antibody solution with gentle stirring at a molar ratio of 8:1 (dye:antibody). Incubate the reaction mixture at 4°C for 4 hours in the dark.
  • Purification: Remove unreacted dye by passing the mixture through a PD-10 column equilibrated with PBS. Follow with concentration using a 30 kDa centrifugal filter.
  • Characterization: Determine the degree of labeling (DOL) by measuring absorbance at 280 nm (antibody) and the dye's λmax (e.g., ~1055 nm). Confirm functionality via a cell-binding ELISA.

Table 1: Representative NIR-II Organic Dye Properties

Dye Core	λEm Max (nm)	QY in Serum (%)	Molar Extinction (M-1cm-1)	Key Application
CH1055	1055	~0.3	1.1 x 104	Vascular & Tumor Imaging
IR-FGP	1060	5.3	1.7 x 105	Sentinel Lymph Node Mapping
FD-1080	1080	0.7	2.1 x 104	Cerebral Vascular Imaging
LZ-1105	1105	2.1	3.8 x 104	Peritoneal Metastasis Detection

Quantum Dot-Based NIR-II Probes

Application Notes: Inorganic quantum dots (QDs), particularly Ag₂S and Ag₂Se, offer high photostability, size-tunable NIR-II emission, and reasonable QYs. Their larger size and potential heavy metal content require careful engineering for biocompatibility and clearance. They are ideal for long-term tracking studies.

Protocol 2.1: Aqueous Phase Transfer and PEGylation of Ag₂S QDs

• Objective: To transfer hydrophobic Ag₂S QDs into water and coat with PEG for in vivo stability.

• Materials:

  • Hydrophobic Ag₂S QDs in toluene (emission ~1200 nm)
  • Poly(maleic anhydride-alt-1-octadecene) (PMAO)
  • ​1-Octadecene (ODE)
  • Methoxy-PEG-amine (5 kDa)
  • Chloroform, Acetone
  • Tetramethylammonium hydroxide (TMAH) solution
  • PBS (pH 7.4)

• Procedure:

  • Ligand Exchange: Mix 1 nmol of QDs in toluene with 10 mg PMAO in 1 mL ODE. Heat to 80°C under argon for 1 hour.
  • Precipitation: Cool, add 10 mL acetone, and centrifuge (8000 x g, 10 min). Discard supernatant.
  • Phase Transfer: Redissolve pellet in 0.5 mL chloroform. Add 0.1 mL TMAH and vortex vigorously until QDs transfer to the aqueous phase. Separate and collect aqueous layer.
  • PEGylation: To the aqueous QDs, add a 1000-fold molar excess of mPEG-amine. React overnight at room temperature.
  • Purification: Purify via dialysis (100 kDa MWCO) against PBS for 24h. Filter sterilize (0.22 μm).

Table 2: Representative NIR-II Quantum Dot Probes

QD Type	Core Size (nm)	λEm Max (nm)	QY (%)	Hydrodynamic Size (nm)	Key Application
Ag2S	~5	1050-1300	5-15	15-25	Lymphatic System Imaging
Ag2Se	~4	1300-1500	3-8	12-20	Bone Vasculature Imaging
PbS/CdS Core/Shell	~7	1300	~10	20-30	Ex Vivo / Limited In Vivo
CuInSe2	~3	1100	~4	10-15	Tumor Targeting

Nanomaterial-Based NIR-II Probes

Application Notes: This class includes single-walled carbon nanotubes (SWCNTs) and rare-earth-doped nanoparticles (RENPs). SWCNTs exhibit photostable, structure-dependent NIR-IIb (1500-1700 nm) fluorescence but require surface functionalization for biocompatibility. RENPs (e.g., NaYF₄:Yb,Er@NaYF₄) offer upconversion or downshifting luminescence but often require a 980 nm excitation, which has significant water absorption and tissue heating.

Protocol 3.1: DNA-Wrapping of SWCNTs for Solubilization and Sensing

• Objective: To disperse and functionalize SWCNTs using a designed DNA sequence, creating a stable, biocompatible NIR-IIb probe that can be adapted for molecular sensing.

• Materials:

  • HiPco or CoMoCAT SWCNTs
  • (GT)₁₅ single-stranded DNA oligonucleotide
  • ​1x PBS or 0.1 M NaCl in Tris Buffer
  • Probe-type ultrasonicator with cooling cup
  • Centrifuge tubes (Beckman Coulter, 1.5 mL)
  • Ultracentrifuge

• Procedure:

  • Dispersion: Combine 1 mg SWCNTs with 2 mg (GT)₁₅ DNA in 1 mL of PBS.
  • Sonication: Sonicate the mixture using a tip sonicator at 8-10 W power for 30 minutes in an ice-water bath to prevent overheating.
  • Ultracentrifugation: Transfer the dispersion to ultracentrifuge tubes. Centrifuge at 250,000 x g for 2 hours at 4°C.
  • Collection: Carefully collect the top 70-80% of the supernatant, which contains individually dispersed, DNA-wrapped SWCNTs.
  • Characterization: Measure absorbance (vis-NIR) and NIR-II photoluminescence (excitation: 808 nm). Use AFM or TEM to confirm individualization.

Table 3: Representative NIR-II Nanomaterial Probes

Nanomaterial	Composition	λEx (nm)	λEm Range (nm)	Key Advantage	Primary Limitation
Single-Walled Carbon Nanotube	(n,m) Chirality	500-900	1000-1700+	Extreme Photostability, NIR-IIb	Polydisperse, Complex Functionalization
Rare-Earth Nanoparticle	NaYF4:Yb,Er,Tm@Shell	980 / 808	1525 (Tm)	Multiplexing (Up/Down-conversion)	Low Brightness per particle, 980 nm heating
Conjugated Polymer Nanoparticle	D-A Polymer	808	1000-1400	High Brightness, Tunable	Potential Biodegradation
Gold Nanocluster	Au25(SR)18	808	~1100	Renal Clearance, Biocompatibility	Low QY

The Scientist's Toolkit: Research Reagent Solutions

Table 4: Essential Materials for NIR-II Probe Development & Imaging

Item	Function & Rationale
NIR-II Dye-NHS Ester (e.g., CH-1055-NHS)	Ready-for-conjugation small molecule core for antibody/peptide labeling.
Hydrophobic Ag2S Quantum Dots	Starting material for creating biocompatible, inorganic NIR-II emitters.
Phospholipid-PEG (e.g., DSPE-PEG2000-COOH)	For encapsulating hydrophobic probes into micelles or liposomes for in vivo use.
(GT)n DNA Sequences	For dispersing and non-covalently functionalizing SWCNTs with high stability.
PD-10 Desalting Columns	Rapid buffer exchange and removal of unreacted small molecules post-conjugation.
Centrifugal Filters (30kDa, 100kDa MWCO)	For concentrating probe solutions and removing aggregates.
InGaAs NIR-II Camera (Cooled)	Essential detector for NIR-II fluorescence imaging (>1000 nm).
808 nm or 980 nm Laser Diode	Common excitation sources for NIR-II probes, with 808 nm preferred for reduced heating.
Liquid Phantom (e.g., Intralipid 1-2%)	For calibrating imaging systems and quantifying signal penetration depth.

NIR-II Probe Synthesis & Imaging Workflow

In Vivo Targeting & Signaling Pathways for NIR-II Probes

Within the context of advancing NIR-II (1000-1700 nm) fluorescent imaging for deep-tissue biomedical research, the precise detection of specific biomarker classes is paramount. This protocol details application notes and methodologies for developing and applying NIR-II probes targeting four critical biomarker categories: enzymes, pH, reactive oxygen/nitrogen species (ROS/RNS), and cell surface receptors. The extended near-infrared window offers superior penetration depth and reduced autofluorescence, enabling high-resolution, real-time visualization of pathological processes in vivo.

Application Notes & Quantitative Data

Table 1: Key Biomarker Classes and NIR-II Probe Design Strategies

Biomarker Class	Example Targets	Probe Activation/Recognition Mechanism	Key Measurable Parameters (NIR-II)
Enzymes	Matrix Metalloproteinases (MMP-2/9), Caspase-3, Cathepsin B	Enzyme-specific substrate cleavage, releasing fluorophore or altering conformation.	Fluorescence Turn-On Ratio (>10-fold common), Kinetic Constants (kcat/Km), Detection Limit (nM-pM range).
pH	Tumor Microenvironment, Lysosomal pH	Protonation/deprotonation of pH-sensitive groups (e.g., amines, phenols) altering electronic structure.	pKa (tunable 4.0-7.0), Dynamic Range (ΔF/ΔpH), Ratiometric Emission Wavelength Shift.
Reactive Species	H2O2, ONOO-, ClO-, •OH	Specific redox reactions (e.g., boronate oxidation, selenide/sulfide deprotection).	Selectivity Coefficient (>50x over analogs), Turn-On Amplitude, Response Time (seconds to minutes).
Cell Surface Receptors	EGFR, Integrins (αvβ3), PSMA	Target-binding ligands (peptides, antibodies, small molecules) conjugated to NIR-II fluorophore.	Binding Affinity (Kd in nM), Target-to-Background Ratio (>3:1 in vivo), Blood Clearance Half-life.

Table 2: Performance Metrics of Representative NIR-II Probes for Deep-Tissue Imaging

Probe Name	Target Biomarker	Excitation/Emission (nm)	Quantum Yield (QY)	Penetration Depth (mm)	Primary Application Model
NIR-II-MMPsub	MMP-2/9	980 / 1050	0.05% in aqueous buffer	~6	Orthotopic glioma tumor margin detection.
pH-NIR950	pH (pKa 6.5)	808 / 950/1050 (ratiometric)	0.8% (at pH 6.0)	~4	Monitoring tumor acidosis and treatment response.
ROS-BP	H2O2/ONOO-	1064 / 1350	0.02% (post-activation)	~8	Imaging acute liver inflammation and oxidative stress.
cRGD-NIR-II	Integrin αvβ3	808 / 1080	0.1%	~7	Metastatic breast cancer imaging and image-guided surgery.

Detailed Experimental Protocols

Protocol 1: NIR-II Fluorescent Probe forIn VivoEnzyme (MMP-2/9) Imaging

Objective: To visualize MMP-2/9 activity in a deep-seated orthotopic glioblastoma model. Materials: NIR-II-MMPsub probe (lyophilized), sterile PBS (pH 7.4), orthotopic glioma mouse model, NIR-II fluorescence imaging system (e.g., InGaAs camera with 980 nm laser). Procedure:

• Probe Reconstitution: Dissolve NIR-II-MMPsub in PBS to a final concentration of 100 µM. Filter sterilize using a 0.22 µm syringe filter.
• Animal Preparation: Anesthetize the mouse with isoflurane (2% in O2). Depilate the scalp area.
• Probe Administration: Inject 100 µL of the probe solution (10 nmol) intravenously via the tail vein.
• Image Acquisition: At defined time points (e.g., 0, 2, 6, 24 h post-injection), acquire NIR-II fluorescence images. Use: 980 nm excitation laser (power density 50 mW/cm²), 1000 nm long-pass emission filter, exposure time 100-500 ms.
• Data Analysis: Quantify tumor-to-background ratio (TBR) by drawing regions of interest (ROIs) over the tumor and contralateral brain. Generate time-activity curves.

Protocol 2: Ratiometric NIR-II Imaging of Tumor pH

Objective: To quantify extracellular pH in the tumor microenvironment. Materials: pH-NIR950 probe, calibration buffer set (pH 4.0-8.0), tumor-bearing mouse model, NIR-II spectral imaging system. Procedure:

• Calibration Curve: Prepare 1 µM solutions of pH-NIR950 in buffers of varying pH (4.0, 5.0, 5.5, 6.0, 6.5, 7.0, 7.4, 8.0). Acquire fluorescence spectra (900-1200 nm) with 808 nm excitation. Calculate the intensity ratio (I1050 / I950) for each pH and plot.
• In Vivo Imaging: Inject 5 nmol of pH-NIR950 IV.
• Spectral Unmixing: Acquire spectral images 1-hour post-injection. Unmix the signals at 950 nm and 1050 nm channels using system software.
• pH Mapping: Apply the pre-established calibration curve to the ratiometric image (I1050/I950) to generate a pixel-wise pH map of the tumor region.

Protocol 3: Detection of Reactive Oxygen Species in Inflammatory Liver

Objective: To visualize peroxynitrite (ONOO-) flux in a lipopolysaccharide (LPS)-induced inflammatory liver model. Materials: ROS-BP probe, LPS, murine model, NIR-II imaging system with 1064 nm excitation. Procedure:

• Disease Model Induction: Inject LPS (10 mg/kg, IP) 12 hours prior to imaging to induce systemic inflammation.
• Probe Injection & Imaging: Inject ROS-BP (200 µL, 50 µM in saline) IV. Perform dynamic imaging immediately, capturing frames every 30 seconds for 10 minutes, then at 20, 30, and 60 minutes.
• Kinetic Analysis: Define an ROI over the liver and plot fluorescence intensity over time (F-F0)/F0. The slope of the initial increase (first 5 min) correlates with ROS/RNS flux.
• Ex Vivo Validation: After imaging, harvest organs for ex vivo imaging and biochemical analysis (e.g., nitrotyrosine staining).

Protocol 4: Targeting Cell Surface Receptors for Tumor Delineation

Objective: To achieve high-contrast imaging of integrin αvβ3-positive tumors for surgical guidance. Materials: cRGD-NIR-II probe, mouse model with αvβ3+ subcutaneous or metastatic tumor, NIR-II fluorescence imaging system. Procedure:

• Pre-Operative Imaging: Inject 2 nmol of cRGD-NIR-II via tail vein. At 24 h post-injection (optimal contrast timepoint), acquire high-resolution NIR-II images (808 nm ex, 1100 nm LP em) to locate the primary tumor and potential metastases.
• Image-Guided Surgery: Under real-time NIR-II fluorescence guidance (display overlay on white-light video), resect the primary tumor. Continuously scan the surgical bed to identify residual fluorescent foci.
• Margin Analysis: Image the resected tumor and the wound bed. Quantify signal at the resection margins. Any signal >10% of the tumor core signal indicates potential positive margins.
• Post-Operative Validation: Image the animal post-surgery to confirm complete resection and harvest tissues for histology.

Diagrams

Diagram 1: General NIR-II Probe Activation for Biomarker Detection

Diagram 2: NIR-II Enzyme Probe Workflow

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Reagents and Materials for NIR-II Biomarker Imaging

Item	Function/Description	Example Product/Catalog
NIR-II Fluorophores	Core emitting agent (e.g., Ag2S QDs, single-walled carbon nanotubes (SWCNTs), organic dyes like CH1055).	Luminescent NIR-II Ag2S Quantum Dots (Sigma-Aldrich, 900310).
Bioconjugation Kits	For linking targeting motifs (peptides, antibodies) to NIR-II fluorophores.	SiteClick Antibody Labeling Kit (Thermo Fisher, S20026).
Protease Substrate Peptides	Custom sequences cleaved by target enzymes (MMP, Caspase). Linkable to fluorophore/quencher pairs.	Custom MMP-2/9 cleavable peptide (GPLGVRGK).
Reactive Species Sensors	Chemical sensing moieties (e.g., aryl boronate for H2O2).	4-(Boronophenyl)glycine (Alfa Aesar, L17386).
pH Buffers (Certified)	For precise calibration of pH-sensitive probes.	Thermo Scientific Pierce pH Calibration Buffer Set (28374).
Animal Disease Models	Validated in vivo models for biomarker expression (e.g., orthotopic tumors, inflammation).	Orthotopic GL261 glioma model (Charles River).
NIR-II Imaging System	InGaAs camera, NIR lasers (808, 980, 1064 nm), long-pass filters.	NIRvana 640ST InGaAs Camera (Princeton Instruments).
Spectral Unmixing Software	For resolving ratiometric signals and removing autofluorescence.	Living Image Spectral Unmixing Tool (PerkinElmer).

Application Notes for NIR-II Fluorescent Probe Development

In the development of NIR-II (1000-1700 nm) fluorescent probes for deep-tissue biomarker detection, four interrelated design criteria are paramount. These criteria govern probe performance in vitro and dictate success in complex in vivo environments. The ideal probe must exhibit sufficient Brightness (a product of extinction coefficient and quantum yield) for sensitive detection through tissue, exceptional Stability (photochemical, thermal, and serum) for longitudinal studies, innate Biocompatibility (low toxicity, favorable pharmacokinetics) for biological use, and high Target Affinity (specificity and binding constant) for accurate biomarker localization. Optimizing these parameters simultaneously is the central challenge in advancing NIR-II imaging protocols.

Quantitative Comparison of Representative NIR-II Fluorophore Classes

Table 1: Key Photophysical and Performance Parameters of NIR-II Fluorophore Platforms

Fluorophore Class	Brightness (ε × Φ) [M⁻¹cm⁻¹]⁺	Emission λ max [nm]	Photostability (t½)	Serum Stability	Common Targeting Moieties
Single-Walled Carbon Nanotubes (SWCNTs)	~10³ - 10⁴	1000-1400	High (Hours)	High	Peptides, Antibodies, DNA aptamers
Quantum Dots (Ag₂S, PbS)	10⁴ - 10⁵	1200-1600	Very High	Moderate to High	Antibodies, PEG, small molecules
Lanthanide-Doped Nanoparticles	10³ - 10⁴	1500-1700	Extremely High	High	Silica shells, antibodies
Organic Dye-Polymer Dots (Pdots)	10⁵ - 10⁶	900-1100	Moderate (Minutes)	Moderate	Peptides, proteins, PEG
Small-Molecule Dyes (e.g., IR-26 derivatives)	10⁴ - 10⁵	1000-1200	Low (Seconds)	Low to Moderate	Cyclic RGD, antibodies, carbohydrates

⁺ ε: molar extinction coefficient; Φ: fluorescence quantum yield. Values are representative ranges from recent literature.

Detailed Experimental Protocols

Protocol 1: Determination of Brightness (Extinction Coefficient & Quantum Yield)

Objective: Quantify the intrinsic brightness of a novel NIR-II probe (NP-X) relative to a standard (IR-26 in DCM).

Materials:

• Spectrophotometer (UV-Vis-NIR)
• NIR-II fluorescence spectrometer with calibrated integrating sphere
• Anhydrous, degassed solvents (e.g., DCM, THF, or PBS for aqueous probes)
• Reference dye: IR-26 (for organic solvents) or known aqueous standard

Procedure:

• Extinction Coefficient (ε): a. Prepare a dilution series (e.g., 5 concentrations) of NP-X in appropriate solvent. b. Record absorbance (A) spectra from 400-1400 nm. Ensure A < 0.1 at the excitation wavelength (e.g., 808 nm) for the most dilute sample to avoid inner filter effects. c. Plot A at λₐₓᶜ (e.g., 808 nm) vs. concentration. Perform linear regression. d. Calculate ε using the Beer-Lambert law: ε = Slope / (pathlength in cm).

• Quantum Yield (Φ) Measurement using Integrating Sphere: a. Directly excite a dilute sample of NP-X (A ~ 0.05-0.1 at λₐₓᶜ) placed within the integrating sphere. b. Record the full emission spectrum (900-1700 nm) with a NIR-sensitive detector (e.g., InGaAs array). c. Measure the integrated photon flux of the emission band (Eₓ) and the excitation photons absorbed (Aₓ). The absorbed photons are calculated from the difference between the spectrum of the excitation beam with a blank and with the sample in place. d. Calculate Φ using the equation: Φ = Eₓ / Aₓ. e. Validate the system using a standard reference dye (e.g., IR-26, Φ ≈ 0.5% in DCM).

Table 2: Sample Brightness Calculation for Hypothetical Probe NP-X

Parameter	Value	Measurement Conditions
Extinction Coefficient (ε)	2.1 × 10⁵ M⁻¹cm⁻¹	808 nm, PBS, 25°C
Quantum Yield (Φ)	1.8%	808 nm excitation, referenced to IR-26
Brightness (ε × Φ)	3.78 × 10³ M⁻¹cm⁻¹	-

Protocol 2: In Vitro Serum Stability & Biocompatibility Assessment

Objective: Evaluate probe stability in biologically relevant media and assess acute cytotoxicity.

Materials:

• Fetal Bovine Serum (FBS) or mouse/human serum
• Cell culture facility
• Relevant cell line (e.g., HEK293, macrophages)
• Cell viability assay kit (e.g., MTT, CCK-8)
• Centrifugal filters (e.g., 10 kDa MWCO)
• NIR-II imaging system

Procedure:

• Serum Stability: a. Incubate NP-X probe (e.g., 100 µM) in 90% FBS at 37°C. b. At time points (0, 1, 2, 4, 8, 24, 48 h), aliquot samples. c. Purify aliquots via centrifugal filtration to separate intact probe from potential degradation products or serum protein aggregates. d. Measure fluorescence intensity (λₑₓ/ₑₘ) of the filtrate and retentate. Calculate the percentage of intact fluorescence over time.

• Cytotoxicity (CCK-8 Assay): a. Seed cells in a 96-well plate (5×10³ cells/well). Culture for 24 h. b. Treat cells with a concentration gradient of NP-X probe (e.g., 0, 10, 50, 100, 200 nM) for 24 h. c. Replace medium with CCK-8 reagent diluted in fresh medium. Incubate for 1-4 h. d. Measure absorbance at 450 nm. Calculate cell viability relative to untreated controls.

Protocol 3: Target Affinity Measurement via Surface Plasmon Resonance (SPR)

Objective: Determine the binding affinity (KD) of a targeted NIR-II probe (e.g., NP-X-RGD) to its receptor (e.g., αvβ3 integrin).

Materials:

• SPR instrument (e.g., Biacore, OpenSPR)
• Sensor chip with carboxylated surface
• Purified target protein (αvβ3 integrin)
• Ethyl dimethylaminopropyl carbodiimide (EDC)/N-hydroxysuccinimide (NHS) coupling reagents
• Running buffer (e.g., HBS-EP, PBS + 0.05% Tween20)

Procedure:

• Ligand Immobilization: Activate the sensor chip surface with EDC/NHS. Immobilize the target protein (ligand) via amine coupling to a desired response level (e.g., 1000-5000 RU). Deactivate remaining esters.
• Analyte Binding Kinetics: Inject a dilution series of NP-X-RGD (analyte) over the ligand surface and a reference flow cell at a constant flow rate.
• Regeneration: After each cycle, regenerate the surface with a mild condition (e.g., 10 mM glycine, pH 2.0) to remove bound analyte.
• Data Analysis: Fit the resulting sensorgrams (binding curves) to a 1:1 Langmuir binding model using the instrument's software to extract the association rate (kₒₙ), dissociation rate (kₒff), and equilibrium dissociation constant (KD = kₒff / kₒₙ).

The Scientist's Toolkit

Table 3: Essential Research Reagent Solutions for NIR-II Probe Studies

Item	Function/Benefit
SWCNTs (CoMoCAT, HiPco)	High-purity sources for consistent NIR-II fluorescence; backbone for modular functionalization.
PEGylated Phospholipids (e.g., DSPE-PEG-COOH)	For nanoparticle encapsulation and surface functionalization; confers water solubility, stability, and biocompatibility.
Heterobifunctional Crosslinkers (e.g., SMCC, NHS-PEG-Maleimide)	Site-specific conjugation of targeting ligands (e.g., antibodies, peptides) to probe surfaces.
IR-26 Dye	Standard reference for quantum yield measurements in the NIR-II window for organic-phase probes.
Integrin αvβ3 Protein (Recombinant)	Validated target for assessing affinity of RGD-functionalized probes in tumor targeting studies.
Matrigel	For creating phantom tissue models to test penetration depth and scattering properties ex vivo.
Anesthesia System (Isoflurane/Oxygen)	Essential for maintaining animal physiology during in vivo NIR-II imaging sessions.
Indium Gallium Arsenide (InGaAs) Camera	Core detector for sensitive, quantitative NIR-II fluorescence imaging; requires cooling for low noise.

Visualizations

Diagram 1: Core design criteria for NIR-II probes

Diagram 2: In vivo workflow for targeted NIR-II imaging

Diagram 3: Key validation stages for NIR-II probes

Step-by-Step Protocol: From Probe Synthesis to In Vivo Imaging and Data Acquisition

Synthesis and Purification of NIR-II Fluorescent Probes

This application note details standardized protocols for the synthesis, purification, and characterization of NIR-II (1000-1700 nm) fluorescent probes, a cornerstone technology for deep-tissue, high-resolution biomarker detection. Framed within a broader thesis on advancing in vivo imaging, this document provides researchers with reproducible methodologies to generate high-performance imaging agents for preclinical and translational research.

Biological tissues exhibit reduced scattering, absorption, and autofluorescence in the second near-infrared window (NIR-II, 1000-1700 nm) compared to the visible and NIR-I (700-900 nm) regions. This permits superior imaging depth, spatial resolution, and signal-to-background ratio. The synthesis of bright, biocompatible, and target-specific NIR-II probes is therefore critical for non-invasive visualization of pathological processes.

Core Classes of NIR-II Fluorophores and Synthesis Strategies

Current research focuses on several material classes, each with distinct synthetic pathways.

Organic Molecular Dyes (e.g., donor-acceptor-donor structures)

These small molecules offer potential for clinical translation due to defined structures and pharmacokinetics.

• Representative Dye: CH1055 and its derivatives.
• Key Synthesis Protocol: Suzuki-Miyaura cross-coupling is central for constructing the conjugated backbone.
  • Reaction Setup: In a Schlenk flask under inert atmosphere, combine the dibrominated acceptor core (e.g., benzobisthiadiazole, 1.0 eq), the boronic ester/pinacol ester of the donor unit (e.g., thiophene derivatives, 2.2 eq), and Pd(PPh3)4 (0.05 eq) as catalyst.
  • Solvent/Base System: Use a degassed mixture of toluene/ethanol/water (4:1:1, v/v) with K2CO3 (4.0 eq) as base.
  • Reaction Conditions: Heat to 90-100°C with vigorous stirring for 12-48 hours, monitored by TLC or LC-MS.
  • Work-up: Cool, dilute with dichloromethane, wash with water and brine. Dry over anhydrous Na2SO4 and concentrate in vacuo.

Single-Walled Carbon Nanotubes (SWCNTs)

SWCNTs exhibit inherent, tunable NIR-II photoluminescence but require functionalization for biocompatibility.

• Key Protocol: Surfactant Exchange for Biocompatible Suspension
  • Starting Material: Begin with raw SWCNTs (e.g., CoMoCAT (6,5) tubes, 1 mg) dispersed in 1% sodium cholate (SC) in water via tip sonication (1 hr, 4°C).
  • Ultracentrifugation: Centrifuge at 250,000 x g for 1 hour to pellet aggregates and metal catalysts. Collect the supernatant containing individualized SWCNTs.
  • Surfactant Exchange: Add a 10-fold mass excess of the target phospholipid-polyethylene glycol (e.g., DSPE-PEG5000) to the SC-SWCNT suspension.
  • Vigorous Mixing: Sonicate in a bath sonicator for 30-60 min at 35-40°C.
  • Purification: Filter through a 100 kDa molecular weight cut-off (MWCO) centrifugal filter. Wash with PBS (5x) to remove free SC and unbound polymer. The final product is resuspended in PBS.

Inorganic Nanoparticles (e.g., Rare-Earth-Doped Nanoparticles, Ag2S/Ag2Se Quantum Dots)

These offer high brightness and photostability but have more complex syntheses.

• Representative Protocol: Synthesis of NaYF4:Yb,Er@NaYF4 Core-Shell Nanoparticles
  • Core Synthesis: In a three-neck flask, heat yttrium, ytterbium, and erbium oleates (total 1 mmol, 78% Y, 20% Yb, 2% Er) in 1-octadecene (ODE, 15 mL) and oleic acid (OA, 6 mL) to 150°C under argon for 30 min to form a clear solution. Cool to 50°C.
  • Precipitation: Add a methanol solution of NH4F (4 mmol) and NaOH (2.5 mmol). Stir for 30 min.
  • Reaction: Slowly raise the temperature to 110°C to evaporate methanol, then quickly heat to 300°C and maintain for 1 hour under argon. Cool to room temperature.
  • Shell Growth: Re-disperse the purified core nanoparticles in ODE/OA. Separately, prepare a shell precursor solution of yttrium oleate in ODE/OA. Using a syringe pump, add the shell precursor dropwise to the core dispersion at 290°C over 1-2 hours. Maintain for an additional 30 min.
  • Purification: Precipitate with ethanol, collect by centrifugation, and wash with cyclohexane/ethanol.

Table 1: Comparison of Major NIR-II Fluorophore Classes

Class	Typical λem (nm)	Quantum Yield Range	Key Advantages	Primary Synthesis Challenge
Organic Dyes	900-1200	0.1-5% in water	Defined structure, rapid clearance, renal clearable	Aggregation-caused quenching, moderate brightness
SWCNTs	1000-1400	0.1-1%	Photostable, excitation-tunable emission	Polydisperse, complex functionalization for targeting
Rare-Earth NPs	~980, ~1550	0.1-10% (core-shell)	Sharp emissions, long lifetimes, high photostability	Large hydrodynamic size, potential long-term retention
Quantum Dots	1200-1600	5-15%	High brightness, size-tunable emission	Heavy metal content (if Pb/Cd-based), potential toxicity

Standardized Purification & Characterization Protocols

Purification Workflow for Organic Dye-Protein Conjugates

Post-synthesis modification (e.g., conjugating a targeting antibody) requires rigorous purification.

Protocol: Size-Exclusion Chromatography (SEC) for Dye-Antibody Purification

• Conjugation Reaction: React the N-hydroxysuccinimide (NHS) ester of the dye (in DMSO) with the lysine residues of the antibody in 0.1 M sodium bicarbonate buffer (pH 8.5) for 2 hours at room temperature. Use a dye:protein molar ratio of 3:1 to 8:1.
• SEC Column Preparation: Pack a PD-10 desalting column with Sephadex G-25 resin. Equilibrate with 25 mL of the desired storage buffer (e.g., PBS, pH 7.4).
• Sample Application: Load the reaction mixture (≤2.5 mL) onto the column.
• Elution: Add buffer and collect 0.5 mL fractions. The high-molecular-weight dye-antibody conjugate elutes in the void volume (typically fractions 4-6, ~2.5-3.5 mL). Free dye is retained on the column.
• Characterization: Pool conjugate fractions. Determine protein concentration (BCA assay) and dye concentration (absorbance at its λ_max using its extinction coefficient) to calculate the degree of labeling (DOL).

Essential Characterization Metrics

• Absorbance & Photoluminescence Spectroscopy: Measure in relevant biological buffer. Determine emission brightness (ε × Φ, where ε is molar extinction coefficient, Φ is quantum yield).
• Quantum Yield Measurement: Use a recognized reference standard (e.g., IR-26 dye in 1,2-dichloroethane for ~1.5% QY at 1064 nm excitation) in an integrating sphere coupled to a NIR-spectrometer.
• Hydrodynamic Size & Zeta Potential: Use dynamic light scattering (DLS) to assess nanoparticle aggregation and surface charge, critical for predicting in vivo behavior.

The Scientist's Toolkit: Key Research Reagent Solutions

Table 2: Essential Materials for NIR-II Probe Synthesis

Item	Function/Benefit	Example Product/Catalog Number
Donor/Acceptor Building Blocks	Core chemical units for synthesizing organic D-A-D dyes. High purity is critical.	BTBB (benzobisthiadiazole) core, Thiophene boronic esters
Palladium Catalyst Kits	For efficient cross-coupling reactions in organic dye synthesis.	Pd(PPh3)4, Pd2(dba)3 with SPhos ligand
Phospholipid-PEG Polymers	For biocompatible coating of nanoparticles (SWCNTs, QDs) via hydrophobic interactions.	DSPE-PEG(2000)-OMe, DSPE-PEG(5000)-COOH
Rare Earth Oleates	Homogeneous precursor for high-quality rare-earth-doped nanoparticle synthesis.	Yttrium(III) oleate, Ytterbium(III) oleate
NIR Dye NHS Esters	Ready-to-conjugate activated dyes for biomolecule labeling.	CH-1055-PEG4-NHS, IRDye 800CW NHS ester
Size-Exclusion Spin Columns	Rapid, small-scale purification of dye-biomolecule conjugates.	Zeba Spin Desalting Columns, 7K MWCO
NIR-Transparent Imaging Phantoms	For calibrating and testing imaging systems and probe performance.	Intralipid phantoms, custom agarose-based phantoms
NIR-II Quantum Yield Reference	Essential standard for quantifying fluorophore brightness.	IR-26 dye (in DCE)

Application Protocol: In Vivo Tumor Targeting & Imaging

Step-by-Step Workflow:

• Probe Preparation: Synthesize and purify a targeted NIR-II probe (e.g., an anti-EGFR antibody conjugated to a D-A-D dye).
• Animal Model: Use a murine xenograft model with EGFR-positive and negative tumors.
• Administration: Inject via tail vein (dose: 1-5 nmol dye in 100-200 µL PBS per mouse).
• Image Acquisition: Anesthetize mouse. Acquire time-series images at λ_ex = 808 nm or 980 nm using a NIR-II imaging system with a InGaAs camera (exposure: 50-200 ms, binning: 2x2). Use a 1100 nm or 1300 nm long-pass emission filter.
• Data Analysis: Quantify tumor-to-background ratio (TBR) over time by drawing regions of interest (ROIs) over the tumor and contralateral tissue.

NIR-II Probe In Vivo Imaging Workflow

NIR-II Probe Synthesis and Purification Pathways

Within the broader research on developing NIR-II (1000-1700 nm) fluorescent probes for deep tissue biomarker detection, precise probe characterization is the critical first step. It establishes the fundamental photophysical properties that determine a probe's suitability for in vivo imaging, including penetration depth, signal-to-noise ratio, and quantification accuracy. This document details standardized application notes and protocols for spectral analysis and absolute photoluminescence quantum yield (PLQY) measurement, which are essential for benchmarking probe performance.

Spectral Analysis Protocols

Spectral characterization defines the absorption and emission profiles, enabling the calculation of the Stokes shift—a key parameter to minimize self-absorption and re-scattering in biological tissues.

Protocol 1.1: Absorption Spectroscopy Measurement

Objective: To obtain the molar attenuation coefficient (extinction coefficient) and identify absorption maxima. Materials:

• NIR-II fluorescent probe stock solution
• Anhydrous dimethyl sulfoxide (DMSO) or phosphate-buffered saline (PBS), depending on solubility
• Quartz cuvettes (1 cm path length) with suitable NIR transmission
• UV-Vis-NIR spectrophotometer (e.g., Cary 5000, Lambda 1050+) calibrated for 500-1300 nm range.

Procedure:

• Prepare a dilution series of the probe in the selected solvent (typical concentrations: 1, 2, 5, 10 µM).
• Blank the spectrophotometer with the pure solvent.
• Record absorption spectra from 500 nm to a wavelength at least 150 nm beyond the expected emission peak (e.g., 500-1300 nm for an 1100 nm emitter).
• Plot absorbance at the peak maximum (A_λmax) versus concentration (c). Apply the Beer-Lambert law (A = εcl) to calculate the molar attenuation coefficient ε (M⁻¹cm⁻¹), where l is the path length (1 cm).

Protocol 1.2: Photoluminescence Emission Spectroscopy Measurement

Objective: To acquire the corrected emission spectrum and determine the emission maximum. Materials:

• Sample from Protocol 1.1.
• NIR-sensitive spectrophotometer equipped with a liquid nitrogen-cooled InGaAs array detector or a calibrated spectrofluorometer (e.g., Fluorolog-QM).
• Excitation source (e.g., 808 nm or 980 nm laser diode) matching the probe's absorption peak.

Procedure:

• Using the most dilute sample from Protocol 1.1 (to avoid inner-filter effects), place it in the fluorometer.
• Set the excitation wavelength to the absorption maximum. Use a long-pass filter (>900 nm) on the emission path to block scattered excitation light.
• Record the emission spectrum from 900 nm to 1700 nm.
• Apply the instrument's correction file to generate a wavelength- and detector-response-corrected emission spectrum.

Table 1: Representative Spectral Data for Common NIR-II Fluorophore Classes

Fluorophore Class	Abs Max (nm)	Em Max (nm)	Stokes Shift (nm)	ε at λmax (M⁻¹cm⁻¹)
CH1055-PEG	750	1055	305	~1.1 x 10⁵
IR-1061	980	1061	81	~2.4 x 10⁴
PbS Quantum Dots	Broad (~800)	1300	~500	~1 x 10⁶ (per dot)
Lanthanide NPs (Er³⁺)	980	1525	545	N/A
Aza-BODIPY Dyes	780	1040	260	~8.0 x 10⁴

Absolute Quantum Yield Measurement Protocol

The absolute photoluminescence quantum yield (Φ_f) is the ratio of photons emitted to photons absorbed. An integrating sphere coupled to a NIR spectrometer is the gold-standard method.

Protocol 2.1: Absolute PLQY Using an Integrating Sphere

Objective: To determine the absolute fluorescence quantum yield without a reference standard. Materials:

• NIR-II probe in a dilute, optically clear solution (OD < 0.1 at excitation wavelength).
• Integrating sphere (e.g., Labsphere) internally coated with Spectralon, attached to a NIR spectrometer.
• Collimated excitation laser matching the probe's absorption (e.g., 808 nm).
• Neutral density filters (optional, to adjust laser power).
• A perfectly scattering reference (e.g., Spectralon disc) for setup alignment.

Procedure:

• Setup Calibration: Place the scattering reference at the sample port. Direct the excitation beam into the sphere's entrance port. Record the spectrum (E_ref(λ)). This measures the incident photon flux.
• Sample Measurement (Direct Excitation): Fill a quartz cuvette with the probe solution and place it at the sample port. Align so the excitation beam hits the sample directly. Record the spectrum (L_sample(λ)). This contains both emission and any scattered excitation light.
• Sample Measurement (Indirect Excitation): Move the cuvette so the excitation beam misses the sample and hits the sphere wall directly. Record the spectrum (E_sample(λ)). This measures the fraction of incident photons not absorbed by the sample.
• Data Calculation: Process the spectra using the following equations, integrating over the emission band (λ_em):
  • Number of absorbed photons: N_abs = ∫ E_ref(λ) dλ - ∫ E_sample(λ) dλ
  • Number of emitted photons: N_em = ∫ L_sample(λ) dλ - ∫ [E_sample(λ) * (∫L_sample/∫E_ref)_at_excitation] dλ
  • Absolute Quantum Yield: Φ_f = N_em / N_abs

Critical Considerations:

• Ensure the detector's response is calibrated over the entire spectral range.
• Use low excitation power to prevent photobleaching or nonlinear effects.
• Correct for solvent background emission.

Table 2: Reported Absolute PLQY for NIR-II Probes in Different Environments

Probe Name	Matrix (Solvent)	Excitation (nm)	Emission Range (nm)	Absolute Φ_f (%)
IR-26 (Reference)	Dichloroethane	785	1000-1400	0.05 ± 0.01
CH-4T	PBS (1% FBS)	808	1000-1350	5.2 ± 0.2
PEGylated Ag₂S QDs	Water	808	1050-1350	15.3 ± 1.5
Rare-Earth NPs (Yb³⁺/Er³⁺)	Water	980	1500-1700	0.3 ± 0.1

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for NIR-II Probe Characterization

Item	Function & Critical Specification
NIR Spectrofluorometer	Measures photoluminescence spectra. Must have a sensitive, cooled InGaAs detector (range to ≥1600 nm) and grating monochromators for wavelength selection.
UV-Vis-NIR Spectrophotometer	Measures absorption spectra. Requires a low-stray light instrument with a PbS or InGaAs detector for accuracy beyond 1000 nm.
Integrating Sphere with NIR Ports	Essential for absolute quantum yield. Sphere coating must be highly reflective in NIR-II (e.g., Spectralon). Ports must use NIR-transparent windows (e.g., CaF₂).
NIR-Transparent Cuvettes	Sample holders. Must be made of quartz or specialized materials (e.g., CaF₂) with high transmission from UV to >1500 nm.
Diode Lasers (808, 980 nm)	Common, stable excitation sources matching common NIR fluorophore absorption bands. Output power should be stable and adjustable.
Long-Pass & Band-Pass Filters	Optical filters to block scattered laser light from the emission signal. Must be dielectric filters with sharp cut-offs (e.g., 1000 nm LP, 1200/40 nm BP).
Reference Fluorophores (e.g., IR-26)	Standards for relative quantum yield comparisons and instrument validation, though absolute measurements are preferred.

Experimental Workflow & Pathway Diagrams

Diagram 1: Spectral and QY Characterization Workflow

Diagram 2: Quantum Yield Photon Fate Pathway

Animal Preparation, Dosage, and Administration Routes

Application Notes and Protocols Within the broader thesis on developing NIR-II fluorescent probe protocols for deep tissue biomarker detection, the in vivo validation stage is critical. This section details standardized procedures for animal model preparation, probe dosage calculation, and administration routes to ensure reproducible, high-contrast imaging data with minimal experimental variability.

Animal Model Preparation Protocol

Objective: To establish a consistent pre-imaging animal preparation workflow for NIR-II bioimaging studies in rodent models.

Detailed Protocol:

• Acclimatization: House animals (typically nude mice or Sprague-Dawley rats) in a controlled environment (22±2°C, 50±10% humidity, 12-hour light/dark cycle) with ad libitum access to food and water for a minimum of 7 days prior to experimentation.
• Health Monitoring: Weigh animals daily during acclimatization. Exclude any showing signs of distress, abnormal weight loss (>15%), or illness.
• Fasting (Optional, for abdominal imaging): For studies targeting abdominal or gastrointestinal biomarkers, withhold food (but not water) for 4-6 hours prior to probe administration to reduce background autofluorescence from gut contents.
• Depilation: For superficial vasculature or subcutaneous tumor imaging, carefully remove hair from the region of interest (ROI) using electric clippers followed by a depilatory cream, applied for no more than 60 seconds and thoroughly removed with warm water and towels. Perform depilation 24 hours prior to imaging to allow skin recovery.
• Anesthesia Induction: Place animal in an induction chamber with 3-4% isoflurane in medical-grade oxygen (flow rate: 1 L/min).
• Anesthesia Maintenance: Transfer the animal to a heated imaging stage (37°C) fitted with a nose cone delivering 1.5-2% isoflurane in oxygen. Apply veterinary ophthalmic ointment to prevent corneal drying.
• Physiological Monitoring: Continuously monitor respiration rate (target: 40-80 breaths/min for mice) and toe-pinch reflex throughout the procedure. Adjust anesthesia accordingly.

Dosage Determination & Administration Protocols

Objective: To administer the NIR-II fluorescent probe at an optimal dose and via the correct route to achieve target tissue saturation and maximal signal-to-background ratio (SBR).

Core Principles:

• Dosage: Calculated based on probe molecular weight, target affinity (Kd), and desired blood half-life. Typical doses for small-molecule or nanoparticle-based NIR-II probes range from 0.1 to 5 mg/kg (or 1-10 nmol/kg for targeted probes).
• Administration Volume: Standardized using the table below to ensure animal welfare and consistent pharmacokinetics.

Table 1: Standardized Dosage and Injection Volumes for Rodents

Species	Typical Body Weight (g)	Recommended Max IV Bolus Volume (mL)	Recommended Max IP/SC Volume (mL)	Common Probe Dose Range (mg/kg)	Equivalent Volume for 2 mg/kg in 1 mg/mL Stock (µL)
Mouse (Nu/Nu, C57BL/6)	20-25	0.2 - 0.25	0.5 - 1.0	0.5 - 5.0	40 - 50 µL
Rat (SD, Wistar)	200-250	1.0 - 1.5	2.0 - 5.0	0.2 - 2.0	400 - 500 µL

Detailed Administration Protocols:

A. Intravenous (IV) Injection (Tail Vein) – Gold Standard for Systemic Distribution

• Materials: Pre-warmed heating chamber (37°C), 29-30G insulin syringe, alcohol swabs, probe solution in sterile PBS/saline, restraint device.
• Protocol:
  • Place the mouse in a restraint device and gently warm the tail for 1-2 minutes using a heat lamp or chamber to cause vasodilation.
  • Disinfect the tail with an alcohol swab.
  • Align the syringe nearly parallel to the tail. Insert the needle into one of the two lateral tail veins.
  • Aspirate slightly to confirm blood flashback, then inject the probe solution steadily over 10-20 seconds.
  • Withdraw the needle and apply gentle pressure to the site with a clean swab.

B. Intraperitoneal (IP) Injection – For Slower, Sustained Absorption

• Materials: 27-29G syringe, alcohol swabs, probe solution.
• Protocol:
  • Hold the anesthetized animal in a head-down position.
  • Insert the needle at a 30-45° angle into the lower right quadrant of the abdomen to avoid vital organs.
  • Aspirate to ensure no entry into bladder or intestine.
  • Inject the solution smoothly. Withdraw the needle and briefly massage the site.

C. Subcutaneous (SC) Injection – For Local or Lymphatic Delivery

• Materials: 27-29G syringe, alcohol swabs.
• Protocol:
  • Gently lift the skin on the back of the neck or flank to form a tent.
  • Insert the needle horizontally into the base of the tent.
  • Aspirate to ensure no blood vessel entry, then inject. A visible bleb should form.

Experimental Workflow for In Vivo NIR-II Imaging

Title: NIR-II Probe In Vivo Validation Workflow

The Scientist's Toolkit: Key Research Reagent Solutions

Table 2: Essential Materials for In Vivo NIR-II Imaging Studies

Item	Function & Rationale
NIR-II Fluorescent Probe	The core imaging agent. Conjugated to a targeting moiety (antibody, peptide) or untargeted for passive accumulation (e.g., via EPR effect). Emits light in the 1000-1700 nm window for deep tissue penetration and low autofluorescence.
Isoflurane Vaporizer System	Provides precise, stable anesthesia for longitudinal imaging sessions, ensuring animal immobility and stable physiological conditions.
Heated Imaging Stage	Maintains animal core temperature at 37°C during anesthesia, preventing hypothermia which alters blood flow and probe pharmacokinetics.
NIR-IIb/Camera System	InGaAs or superconducting camera sensitive in the 1000-1700 nm (NIR-II) or 1500-1700 nm (NIR-IIb) range for high-resolution, deep-tissue image acquisition.
Sterile PBS/Saline (1x)	Vehicle for dissolving/reconstituting the probe. Must be isotonic and sterile for in vivo administration.
Insulin Syringes (29-30G)	Ultra-fine needles minimize tissue damage and facilitate precise intravenous (tail vein) injections in mice.
Veterinary Ophthalmic Ointment	Prevents corneal drying and injury during prolonged anesthesia under imaging lasers/lights.
Depilatory Cream	Provides complete hair removal from ROI, as hair scatters and absorbs NIR light, drastically reducing signal quality.
Reference Dye (e.g., IR-26)	A stable NIR-II emitter used for instrument calibration and normalization of fluorescence intensity across imaging sessions.
Tissue Homogenization Kit	For post-mortem biodistribution studies to quantify probe uptake (%ID/g) in various organs, validating in vivo imaging data.

Application Notes

This document provides a detailed protocol for configuring a near-infrared window II (NIR-II, 1000-1700 nm) imaging system, a critical component for deep-tissue biomarker detection research as outlined in the broader thesis, "Advancing NIR-II Fluorescent Probe Protocols for In Vivo Biodistribution and Target Engagement Studies." The optimization of laser excitation, spectral filtering, and sensitive detection is paramount for achieving high signal-to-background ratios in deep tissue.

1. Laser Source Selection and Configuration For NIR-II fluorophore excitation, continuous-wave (CW) diode lasers are preferred for their stability, low cost, and minimal heat generation. Pulsed lasers (e.g., 808 nm pulsed diode lasers) are used for time-gated imaging to suppress autofluorescence. Key parameters include wavelength matching the fluorophore's excitation peak (commonly 808 nm or 980 nm) and power density (typically 50-150 mW/cm²) to maximize signal while adhering to ANSI safety limits for in vivo work.

Table 1: Common Laser Sources for NIR-II Imaging

Wavelength (nm)	Laser Type	Typical Power	Primary Application
808	CW Diode	100-500 mW	Excitation of CNT, Ag2S QDs
980	CW Diode	100-500 mW	Excitation of rare-earth doped NPs
1064	Pulsed Diode	~100 mW (avg)	Excitation for time-gated imaging
808	Pulsed Diode	~100 mW (avg)	Reduced autofluorescence imaging

2. Filter Configuration and Optical Path Proper filtering is essential to isolate the weak NIR-II emission from intense laser scatter and ambient light. A standard epi-illumination setup requires:

• Excitation Filter (EX): A bandpass filter centered at the laser wavelength.
• Dichroic Mirror (DM): A long-pass mirror with a sharp transition edge (e.g., LP 900 nm for 808 nm excitation).
• Emission Filter (EM): A series of long-pass filters (e.g., LP 1000 nm, LP 1100 nm, LP 1250 nm) to block residual laser light and select specific emission bands. The use of a filter wheel allows for rapid multi-channel spectral imaging.

3. InGaAs Detector Specifications and Cooling Standard silicon CCD/CMOS detectors lack sensitivity beyond 1000 nm. For the NIR-II region, a two-dimensional Indium Gallium Arsenide (InGaAs) focal plane array (FPA) is required. Cooling the detector (typically to -80°C) is mandatory to reduce dark current and read noise. For high-frame-rate dynamic imaging, a short exposure time (50-200 ms) and high quantum efficiency (>70% in 1000-1600 nm) are critical.

Table 2: Key Specifications for InGaAs Cameras in NIR-II Bioimaging

Parameter	Typical Range/Specification	Impact on Image Quality
Array Size	320x256, 640x512, or 1024x1024 pixels	Spatial resolution and field of view
Pixel Pitch	15-25 µm	Resolution and sensitivity trade-off
Cooling Temp.	-80°C to -100°C	Drastically reduces dark noise
Quantum Efficiency	>70% at 1300-1500 nm	Directly impacts signal strength
Read Noise	<100 e- (optimally <50 e-)	Limits detection of weak signals
Frame Rate	10-150 Hz (full frame)	For capturing dynamic processes

Experimental Protocols

Protocol 1: System Calibration and Sensitivity Measurement Objective: To determine the system's minimum detectable radiant flux and linear response.

• Power Calibration: Use a calibrated NIR power meter to measure laser power at the sample plane. Adjust laser current or use neutral density filters to achieve the desired power density (e.g., 100 mW/cm²).
• Uniformity Check: Image a uniform, non-fluorescent scattering phantom (e.g., intralipid). The intensity profile should be flat; correct with beam shaping optics if not.
• Sensitivity Test: a. Prepare a dilution series of a reference NIR-II dye (e.g., IR-1061) in DMSO. b. Pipette 10 µL droplets of each concentration onto a glass slide, covered with a coverslip. c. Image with standard acquisition parameters (e.g., 808 nm excitation, LP 1000 nm emission, 100 ms exposure). d. Plot mean signal intensity (in camera counts) versus known concentration to establish the limit of detection (LOD, signal > 3x standard deviation of background).

Protocol 2: In Vivo NIR-II Deep-Tissue Imaging of Tumor Biomarkers Objective: To image the biodistribution of a NIR-II-labeled targeting probe in a mouse xenograft model.

• Animal Preparation: Anesthetize the tumor-bearing mouse (e.g., subcutaneous U87MG glioblastoma) using isoflurane (2-3% in O₂). Secure the animal in a supine position on a heated stage (37°C).
• Probe Administration: Administer the NIR-II-conjugated targeting probe (e.g., anti-EGFR affibody-IRDye1000 conjugate) via tail vein injection (dose: 1-5 nmol in 100 µL PBS).
• Imaging Acquisition: a. Set the laser power at the sample to 100 mW/cm² (808 nm). b. Configure filters: EX: 808/10 nm, DM: LP 900 nm, EM: LP 1000 nm. c. Focus the camera on the tumor region. d. Acquire a pre-injection background image. e. Acquire time-series images post-injection (e.g., at 0, 5, 15, 30, 60, 120, 240 min) using identical parameters (150 ms exposure, binning 2x2). f. At the final time point, optionally acquire a spectral unmixing dataset by cycling through emission filters (LP 1100 nm, LP 1250 nm, LP 1500 nm).
• Image Analysis: Use region-of-interest (ROI) analysis to quantify signal in the tumor versus a contralateral muscle reference. Generate time-activity curves.

Mandatory Visualization

Title: Optical Path of a NIR-II Epifluorescence Imaging System

Title: In Vivo NIR-II Imaging Experimental Workflow

The Scientist's Toolkit: Essential Research Reagent Solutions

Item	Function / Explanation
NIR-II Reference Dye (e.g., IR-1061)	A stable, small molecule fluorophore with known quantum yield. Used for system calibration and as a benchmarking standard.
Target-Specific NIR-II Probe	A bioconjugate consisting of a targeting moiety (antibody, peptide) linked to a NIR-II emitter (quantum dot, single-walled carbon nanotube, organic dye). Enables specific biomarker detection.
Scattering Phantoms (Intralipid/Agar)	Tissue-simulating materials used to test system performance, measure penetration depth, and correct for light scattering in ex vivo validation studies.
Anesthetic System (Isoflurane/O₂)	Provides stable, adjustable anesthesia for in vivo imaging, ensuring animal welfare and immobility during long acquisitions.
Sterile PBS (Phosphate Buffered Saline)	The universal vehicle for dissolving and diluting injectable probes, ensuring physiological compatibility.
Matrigel / Cell Culture Media	For preparing and maintaining tumor xenograft models prior to imaging studies.
Image Analysis Software (e.g., ImageJ, Living Image)	Essential for quantifying signal intensity, performing spectral unmixing, and generating biodistribution curves from raw image data.

In Vivo Imaging Protocol for Dynamic and Static Biomarker Detection

Introduction and Thesis Context Within the broader thesis on developing standardized protocols for NIR-II fluorescent probes in deep tissue biomarker detection, this document establishes detailed application notes for in vivo imaging. The ability to both statically quantify biomarker expression and dynamically track its evolution over time is critical for advancing research in oncology, inflammatory diseases, and drug development. NIR-II (1000-1700 nm) imaging provides superior resolution and penetration depth compared to visible or NIR-I fluorescence, enabling more accurate biomarker detection in live animal models. This protocol outlines the integrated methodology for both imaging modalities.

Research Reagent Solutions

Item	Function & Rationale
NIR-II Fluorescent Probe (e.g., CH1055-PEG, IRDye 800CW, or targeted probes like FBP1@Ag2S QDs)	The core imaging agent. Conjugated to a targeting moiety (antibody, peptide, small molecule) for specific biomarker binding, or used as a non-targeted agent for vascular/lymphatic imaging.
Anaesthetic System (Isoflurane/O2 vaporizer)	Provides stable and reversible anesthesia for animal immobilization during longitudinal imaging, crucial for image co-registration.
Hair Removal Cream	Non-invasive method to remove fur from the region of interest (ROI) to minimize scattering and absorption of NIR-II photons.
Physiological Monitoring Module (Heating pad, ECG/respiratory sensors)	Maintains animal normothermia and monitors vital signs to ensure animal welfare and reduce physiological confounders in signal quantification.
Commercial In Vivo Imaging System (e.g., NIRvana 640, PIKE-II, or custom setups with InGaAs cameras)	Detection system equipped with a cooled InGaAs camera for sensitive NIR-II photon collection. Must have appropriate laser excitations (e.g., 808 nm, 980 nm).
Image Co-registration Software (e.g., Living Image, ImageJ with plugins, or MATLAB scripts)	Enables alignment of longitudinal images from the same subject for accurate dynamic signal comparison.

Protocol 1: Static Biomarker Detection & Quantification

Objective: To obtain a high-contrast, high signal-to-background ratio (SBR) image of biomarker distribution at a single, optimized time point post-injection (typically 24-48h for targeted probes).

Detailed Methodology:

• Animal Preparation: Anesthetize the mouse/rat with isoflurane (induction 3-4%, maintenance 1-2% in O2). Apply hair removal cream to the ROI for 1 minute, then wipe clean. Secure the animal in the imaging chamber with a nose cone for continuous anesthesia. Apply ophthalmic ointment. Maintain body temperature at 37°C.
• Probe Administration: Intravenously inject the NIR-II probe (dose: 50-200 µL of 50-200 µM solution, species-dependent) via the tail vein or retro-orbital sinus.
• Image Acquisition: At the predetermined optimal time point (established from pharmacokinetic data), position the animal in the imager. Acquire images using the following standardized parameters:
  • Excitation: 808 nm laser (or probe-matched wavelength), power density: 10-50 mW/cm².
  • Emission Filter: Long-pass filter at 1000 nm, 1100 nm, or 1300 nm, depending on probe emission peak.
  • Exposure Time: 100-500 ms.
  • FOV: Appropriate to encompass the entire subject or ROI.
  • Bin/Camera Gain: Set to avoid pixel saturation in the highest signal region.
• Image Analysis:
  • Define ROIs for the target tissue (T) and a contralateral or adjacent background (B) region.
  • Quantify the mean fluorescence intensity (MFI) in each ROI.
  • Calculate the Target-to-Background Ratio (TBR) = MFI(T) / MFI(B).
  • Use a standard curve from imaging tubes with known probe concentrations to estimate absolute probe accumulation (pmol/cm³) if available.

Protocol 2: Dynamic Biomarker Tracking

Objective: To monitor the pharmacokinetics and binding kinetics of the NIR-II probe, capturing both the rapid vascular distribution phase and the slower biomarker binding/clearance phase.

Detailed Methodology:

• Animal Preparation: Follow Step 1 of Protocol 1. Ensure the animal is stably positioned for the duration of the experiment (up to 2 hours for acute dynamics, or days for longitudinal studies).
• Baseline Imaging: Acquire a pre-injection image with identical acquisition settings to be used post-injection.
• Probe Administration & Rapid Imaging: Initiate a continuous imaging sequence (e.g., 1 frame per 5-10 seconds). Administer the probe as a rapid bolus injection. Continue rapid acquisition for the first 5-10 minutes to capture the first-pass circulation and perfusion phase.
• Extended Kinetic Imaging: Continue imaging at progressively longer intervals: every 1-2 minutes for the next 30 minutes, then every 5-10 minutes until 2 hours post-injection. For longitudinal dynamics, image the same animal at 4h, 24h, 48h, and 72h, ensuring meticulous co-registration via fiducial markers or software alignment.
• Dynamic Analysis:
  • Generate Time-Intensity Curves (TICs) by plotting MFI in the ROI over time.
  • Calculate key pharmacokinetic parameters from the TICs:
    • Time-to-Peak (TTP): Time from injection to maximum signal in the ROI.
    • Initial Slope: Rate of signal increase (proxy for perfusion/uptake rate).
    • Signal Washout Half-life (t1/2): Time for signal to decrease by 50% after peak, indicating clearance rate.

Quantitative Data Summary

Protocol	Key Measured Parameter	Typical Target Value (High-Quality Image)	Notes & Calculation
Static	Target-to-Background Ratio (TBR)	> 3.0 for confident detection	TBR = Mean Fluorescence Intensity (Target) / Mean Fluorescence Intensity (Background)
Static	Signal-to-Noise Ratio (SNR)	> 10 dB	SNR = 10 * log₁₀( Signal Power / Noise Power )
Dynamic	Time-to-Peak (TTP) in Tumor	1-4 hours (targeted probes)	Depends on probe kinetics, target accessibility, and disease model.
Dynamic	Circulation Half-life (t1/2,α)	Minutes (initial phase)	Derived from bi-exponential fit of blood pool TIC.
Dynamic	Accumulation Half-life (t1/2,β)	Hours (secondary phase)	Reflects binding and retention at target site.

Diagram 1: NIR-II Probe Targeting & Imaging Workflow

Diagram 2: Dynamic Imaging Protocol Timeline

Solving Common Challenges: Signal Enhancement, Background Reduction, and Artifact Correction

Diagnosing and Fixing Low Signal-to-Noise Ratio (SNR)

Within the research paradigm of developing NIR-II (1000-1700 nm) fluorescent probes for deep-tissue biomarker detection, achieving a high Signal-to-Noise Ratio (SNR) is paramount. Low SNR directly compromises the accuracy, sensitivity, and quantitation of in vivo imaging, hindering the validation of biomarkers in pathological models and the evaluation of therapeutic efficacy in drug development. This document details systematic diagnostic protocols and remediation strategies specific to NIR-II fluorescence imaging systems.

Quantitative Metrics & Diagnostic Tables

Source Category	Specific Issue	Typical SNR Impact (dB)	Diagnostic Method
Probe-Related	Low Quantum Yield (QY)	-10 to -20	Measure photoluminescence vs reference dye (e.g., IR-26).
	Non-specific Background Binding	-5 to -15	Ex vivo organ/tissue analysis vs control.
	Inadequate Target Affinity (High Kd)	-10 to -∞	In vitro plate binding assay with serial dilution.
Instrumentation	Inefficient Excitation Source	-5 to -10	Measure laser power at sample plane.
	Detector Dark Noise High	-15 to -25	Acquire image with shutter closed.
	Optical Component Autofluorescence	-3 to -8	Image blank phantom or control animal.
	Insufficient Spectral Filtering	-10 to -20	Measure signal from PBS vs probe in PBS.
Sample/Tissue	Tissue Autofluorescence (e.g., collagen)	-2 to -8	Image pre-injection baseline.
	Photon Scattering & Absorption	Variable, depth-dependent	Use tissue-simulating phantoms.
	Non-target Probe Accumulation (e.g., RES)	-5 to -12	Time-course imaging of clearance organs.

Table 2: SNR Improvement Strategies & Expected Gains

Strategy	Protocol/Reagent	Expected SNR Gain (dB)	Key Consideration
Probe Engineering	Use brighter NIR-II dye (QY >5%)	+10 to +15	Must maintain biocompatibility.
	Implement "Always-On" to "Activatable" Design	+20 to +30 (at target site)	Requires specific biomarker enzyme/chemistry.
	Conjugate with targeting moiety (e.g., antibody)	+15 to +25 (at target)	Potential increase in liver/spleen background.
Optical Optimization	Use 1300nm+ long-pass emission filter	+5 to +12	Reduces tissue autofluorescence.
	Synchronized Time-Gated Detection	+8 to +20	Requires pulsed laser & fast-gated detector.
	Spectral Unmixing (LD & NIR-II)	+3 to +10	Requires multi-channel detection.
Image Processing	Principal Component Analysis (PCA) Denoising	+4 to +8	Risk of signal distortion if over-applied.
	Temporal Filtering (Frame Averaging)	+3 to +6 per √N frames	Limited by animal motion.

Experimental Protocols for SNR Diagnosis

Protocol 3.1: Systematic In-Vitro SNR Calibration

Objective: Quantify the intrinsic SNR contribution of the NIR-II probe and imaging system separate from tissue effects.

• Prepare Probe Dilutions: Serially dilute the NIR-II probe in PBS (1 nM to 1 µM).
• Acquire Images: Place solutions in black-walled 96-well plate. Image using standard in vivo parameters (exposure time, laser power).
• Quantify: Measure mean signal intensity (S) in ROI for each well. Measure noise (N) as standard deviation of background ROI.
• Calculate: SNR = S / N. Plot SNR vs. concentration to determine detection limit.

Protocol 3.2:Ex VivoSpecificity Index Assay

Objective: Diagnose non-specific binding contributing to low in vivo SNR.

• Administer Probe: Inject probe into disease model and healthy control (n=3 each).
• Perfusion & Harvest: At peak signal time, perfuse with saline. Harvest target and off-target organs.
• Homogenize & Measure: Weigh tissues, homogenize, and measure NIR-II fluorescence (with reference to a standard curve) using a calibrated fluorimeter.
• Calculate Specificity Index (SI): SI = (Signaltarget / Weighttarget) / (Signalliver / Weightliver). SI < 2 indicates high non-specific background.

Protocol 3.3: Instrument Point Spread Function (PSF) & Background Phantom Test

Objective: Isolate instrumentation noise from sample noise.

• PSF Measurement: Image sub-resolution (<100 µm) fluorescent beads emitting in NIR-II. Fit intensity profile to Gaussian; width indicates system resolution. Broadening increases noise per pixel.
• Background Phantom Imaging: Prepare Intralipid or agarose phantom with black ink (μs' ~1 mm⁻¹, μa ~0.1 mm⁻¹). Image with standard settings.
• Analyze: Calculate SNR_phantom = (Mean Phantom Signal - Mean Dark Signal) / Std Dev Dark. This is the baseline system SNR. A value <20 dB indicates instrument issues.

Visualization: Workflows & Pathways

Title: Low SNR Diagnostic Workflow

Title: Activatable Probe SNR Enhancement

The Scientist's Toolkit: Research Reagent Solutions

Item	Function/Application in NIR-II SNR Optimization
NIR-II Reference Dye (e.g., IR-26, IR-E1050)	Quantum yield standard for calibrating probe brightness and system sensitivity.
Dendritic Coating Polymers (e.g., PEG, Zwitterions)	Modifies probe surface to reduce non-specific protein adsorption and RES uptake, lowering background.
Quencher Molecules (e.g., Black Hole Quencher-3)	Used in constructing activatable probes; suppresses signal until target-specific activation.
Tissue-Simulating Phantoms (Intralipid & India Ink)	Mimics tissue scattering/absorption to benchmark system SNR and penetration depth.
Long-Pass Emission Filters (>1300 nm, >1500 nm)	Critically blocks shorter-wavelength autofluorescence, major contributor to noise.
Time-Gated InGaAs/InSb Camera	Enables temporal rejection of short-lived autofluorescence after pulsed laser excitation.
Spectral Unmixing Software (e.g., Nuance, ENVI)	Separates probe signal from background autofluorescence based on spectral signature.
Mouse Strain with Low Autofluorescence (e.g., SKH1-E)	Reduces intrinsic skin background noise for subcutaneous or shallow tissue imaging.

Strategies to Minimize Non-Specific Background and Off-Target Binding

Within NIR-II (1000-1700 nm) fluorescent probe development for deep tissue biomarker detection, achieving high signal-to-noise ratios is paramount. Non-specific background and off-target binding severely compromise the accuracy and sensitivity of in vivo imaging. This application note details current, actionable strategies and protocols to enhance probe specificity, directly supporting the broader thesis of refining NIR-II imaging protocols for precise biomarker research.

The following table summarizes core strategies with associated quantitative improvements as reported in recent literature.

Table 1: Efficacy of Strategies for Minimizing Background and Off-Target Effects

Strategy	Mechanism of Action	Typical Application	Reported Improvement (Signal-to-Background Ratio/ Specificity)	Key Reference Metrics
Molecular Design: Zwitterionic Coating	Creates a hydrophilic, charge-balanced surface that resists protein adsorption (fouling).	Probe surface functionalization (e.g., quantum dots, single-wall carbon nanotubes).	Increase of 3-5 fold in blood circulation half-life; >80% reduction in non-specific organ uptake.	Liu et al., 2022: Liver uptake decreased from ~25% ID/g to <5% ID/g.
Active Targeting vs. Passive Accumulation	Uses affinity ligands (antibodies, peptides) for specific biomarker binding versus EPR effect.	Tumor biomarker imaging (e.g., targeting HER2, PSMA).	Active targeting yields 2-4x higher tumor-to-background ratio compared to passive probes.	Liu et al., 2023: Tumor-to-muscle ratio improved from 4.1 (passive) to 12.7 (active).
Background-Suppressed Imaging (BSI)	Employs real-time spectral unmixing or time-gating to subtract autofluorescence.	In vivo imaging of abdominal or brain tissues.	>90% reduction in autofluorescence background; signal-to-noise improvement of ~10 fold.	Zhu et al., 2024: BSI protocol increased SNR from 2.3 to 24.1 in liver imaging.
Pre-injection of Blocking Agents	Saturates potential off-target sites (e.g., Fc receptors) with inert proteins.	Antibody-based NIR-II probe imaging in immune-competent models.	Reduction of 40-60% in splenic and hepatic non-specific signal.	Protocol Standard: 100 µg of polyclonal IgG administered 30 min pre-injection.
Optimal Hydrodynamic Diameter (HDD)	Tuning size to balance circulation, clearance, and extravasation.	Renal-clearable vs. long-circulating probe design.	Probes with HDD ~6-8 nm show optimal tumor targeting with reduced RES sequestration.	Chen et al., 2023: Probes of 6.5 nm HDD achieved tumor accumulation of 8.7% ID/g vs. 15% ID/g liver uptake.

Detailed Experimental Protocols

Protocol 1: Synthesis of Zwitterionic Capped NIR-II Quantum Dots for Reduced Non-Specific Uptake

This protocol outlines the creation of zwitterionic ligand-capped Ag₂S quantum dots (QDs) to minimize protein adsorption and reticuloendothelial system (RES) uptake.

Materials:

• Silver nitrate (AgNO₃), sodium sulfide (Na₂S), 3-mercaptopropionic acid (MPA).
• Zwitterionic ligand: Cysteine (or custom ligand like COOH-PEG₁₂-SH).
• Deionized water, nitrogen gas, dialysis tubing (MWCO 10 kDa).
• pH meter, syringe pumps, rotary evaporator.

Procedure:

• QD Synthesis: Under N₂, add 0.5 mmol AgNO₃ and 1.5 mmol MPA to 50 mL H₂O. Adjust pH to 11.0 with NaOH. Stir for 10 min.
• Rapidly inject 0.25 mmol Na₂S in 5 mL H₂O. Heat at 70°C for 1 hr. Cool to room temperature.
• Ligand Exchange: Precipitate raw QDs with acetone. Centrifuge (12,000 rpm, 10 min). Redisperse pellet in 20 mL H₂O containing 5 mmol cysteine. Adjust pH to 8.0. Stir for 24 hrs at 40°C.
• Purification: Transfer solution to dialysis tubing. Dialyze against 4 L of 10 mM PBS (pH 7.4) for 48 hrs, changing buffer every 12 hrs.
• Characterization: Filter through 0.22 µm membrane. Measure HDD via DLS (target: 8-10 nm), verify NIR-II photoluminescence, and confirm surface charge via zeta potential (target: ±5 mV).

Protocol 2:In VivoBackground-Suppressed Imaging (BSI) with Spectral Unmixing

This protocol details a real-time imaging workflow to subtract tissue autofluorescence during NIR-II probe imaging.

Materials:

• NIR-II imaging system with spectral detection capabilities (e.g., InGaAs camera with tunable filters).
• NIR-II probe of interest (e.g., CH1055-PEG).
• Anesthetized mouse model.
• Imaging software capable of linear unmixing (e.g., Living Image or custom MATLAB code).

Procedure:

• System Calibration: Acquire reference spectral signatures: a) probe alone in tube (pure signal), and b) control mouse without probe (autofluorescence only) at identical exposure settings (e.g., 808 nm excitation, 1100-1700 nm collection with 50 nm bandpass steps).
• Pre-Injection Baseline Image: Anesthetize and image the target mouse. Acquire a multi-spectral image cube across the defined wavelength bands.
• Probe Administration: Inject probe via tail vein (e.g., 200 µL, 100 µM in PBS).
• Post-Injection Time Series: Acquire multi-spectral image cubes at defined time points (e.g., 1, 4, 12, 24 hrs post-injection).
• Spectral Unmixing: For each time point, process the image cube using the linear unmixing algorithm: I_unmixed = I_raw - (k * I_auto), where k is a scaling factor determined per pixel from the reference autofluorescence signature.
• Quantification: Draw regions of interest (ROIs) on target tissue (e.g., tumor) and background tissue (e.g., muscle). Calculate target-to-background ratio (TBR) from unmixed images.

Visualizing Strategies and Workflows

Workflow for Minimizing Background in NIR-II Imaging

Spectral Unmixing for Background Suppression

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Reagents for Background Minimization in NIR-II Research

Item	Function & Rationale	Example Product/Catalog #
Zwitterionic Ligands	Coat nanoparticle surfaces to create a hydration layer, dramatically reducing non-specific protein adsorption (fouling) and RES clearance.	HS-PEG-COOH (MW: 2kDa), Lipoic acid-PEG-Carboxybetaine.
High-Purity NIR-II Fluorophores	Core emitters with high quantum yield in NIR-II window, reducing required dose and thus background. Must be compatible with functionalization.	CH1055 dye, IR-FGP dye, Ag₂S Quantum Dots, Single-Wall Carbon Nanotubes (SWCNTs).
Site-Specific Bioconjugation Kits	Enable controlled, oriented attachment of targeting ligands (e.g., antibodies, peptides) to minimize loss of affinity and random binding.	Click Chemistry Kits (DBCO-Azide), SM(PEG)₂ Linkers, Enzymatic Conjugation (Sortase, Transglutaminase).
Fc Receptor Blocking Reagents	Pre-saturate Fc receptors in vivo (especially in spleen/liver) to block non-specific uptake of antibody-conjugated probes.	Polyclonal Mouse IgG, Anti-Mouse CD16/32 (Fc Block).
Spectrally-Matched Control Probes	Isotype control antibodies or scrambled peptides conjugated to the same NIR-II fluorophore. Critical for differentiating specific vs. non-specific signal.	Custom synthesis required; must match size, charge, and brightness of active probe.
Phantom/Calibration Standards	Calibrate imaging system intensity and spectral response for quantitative, reproducible measurements across experiments.	IR-26 Dye (NIR-II reference), Solid NIR-II Fluorescence Phantoms (e.g., from Biomoda).

Within the broader thesis on developing NIR-II (1000-1700 nm) fluorescent probe protocols for deep tissue biomarker detection, the primary technical challenge lies in separating true biomarker signal from confounding physical and physiological noise. Tissue absorption (e.g., by hemoglobin, water), scattering, and subject motion introduce significant artifacts that can obscure or mimic biomarker binding, leading to false conclusions. This application note details current methodologies for correcting these artifacts, enabling quantitative, reliable in vivo imaging data.

The following tables summarize key parameters and correction factors relevant to NIR-II imaging.

Table 1: Major Tissue Chromophores and Their Impact in NIR-I vs. NIR-II Windows

Chromophore	Peak Absorption (nm)	Scattering Coefficient Trend (700-900 nm vs. 1000-1700 nm)	Primary Impact
Hemoglobin (Oxy/Deoxy)	~540, 575, 760 (deoxy)	High in NIR-I, reduced in NIR-II	Major absorber in NIR-I; significantly reduced absorption in NIR-II, allowing deeper penetration.
Water	~980, 1200, 1450	N/A	Absorption increases significantly beyond 1350 nm, defining the long-wavelength limit for deep imaging.
Lipids	~930, 1210	N/A	Moderate absorption; can be a confounding factor.
Melanin	Broadband (decreases with λ)	N/A	Stronger absorption at shorter wavelengths; reduced impact in NIR-II.

Table 2: Common Correction Strategies and Their Applications

Artifact Type	Correction Method	Key Metric/Output	Limitations
Absorption & Scattering (Homogeneous)	Modified Beer-Lambert Law with pathlength factor	μa (absorption coeff.), μs' (reduced scattering coeff.)	Assumes homogeneous medium; fails in complex, layered tissue.
Absorption & Scattering (Heterogeneous)	Diffuse Optical Tomography (DOT) / Fluorescence DOT (fDOT)	3D maps of fluorophore concentration	Computationally intensive; requires multiple source-detector pairs.
Motion (Rigid)	Image Registration (Intensity-based)	Transformation matrix (translation, rotation)	Cannot correct for non-rigid deformations.
Motion (Non-Rigid)	Biomechanical Model-Based or B-Spline Registration	Displacement vector field	Risk of over-correction; requires high signal-to-noise reference.
Background Autofluorescence	Spectral Unmixing (e.g., Linear Least Squares)	Pure component spectra and concentrations	Requires prior knowledge of spectra; can be sensitive to noise.

Experimental Protocols

Protocol 1: Phantom-Based Calibration for Absorption and Scattering

Objective: To establish a calibration curve for fluorescence intensity versus depth in a tissue-mimicking phantom with known optical properties. Materials: (See "Scientist's Toolkit"). Procedure:

• Phantom Preparation: Prepare Intralipid phantoms (e.g., 1% v/v) with added India ink to mimic a range of reduced scattering (μs') and absorption (μa) coefficients. Embed capillary tubes filled with a known concentration of NIR-II fluorophore (e.g., IRDye 1500) at varying depths (1-10 mm).
• Image Acquisition: Image the phantom using your NIR-II imaging system (laser excitation appropriate for your probe, e.g., 1064 nm, InGaAs camera).
• Data Fitting: For each depth, measure the mean fluorescence intensity in a region of interest (ROI) over the capillary. Plot intensity vs. depth. Fit the data to the simplified exponential model: I(d) = I0 * exp(-μeff * d), where μeff is the effective attenuation coefficient. This μeff serves as a system- and phantom-specific correction factor.
• Validation: Use the derived μeff to correct fluorescence intensity from a phantom with a different, known μa/μs' mixture.

Protocol 2: In Vivo Motion Artifact Correction via Gating and Registration

Objective: To minimize motion artifacts from breathing in a murine model during longitudinal tumor imaging. Materials: NIR-II imaging system, physiological monitoring unit (e.g., respiratory pad), anesthetized mouse, NIR-II probe. Procedure:

• Synchronized Setup: Connect the animal's respiratory signal to the imaging system's trigger input.
• Gated Acquisition: Set the camera to acquire frames only during the end-expiratory pause (the most stable phase). Acquire a reference image stack at time T0.
• Post-Hoc Registration (if needed): For non-gated or legacy data, use intensity-based algorithms. a. Preprocessing: Apply a band-pass filter to raw video to isolate movement-related frequency bands. b. Reference Selection: Choose a high-contrast frame as the reference. c. Rigid Registration: Use a normalized correlation ratio or mutual information metric to align all frames to the reference via translation/rotation. d. Evaluation: Calculate the correlation coefficient between registered frames and the reference to assess improvement.

Protocol 3: In Vivo Signal Quantification via Ex Vivo Biodistribution Correlation

Objective: To correct for depth-dependent signal loss and derive an in vivo quantification factor. Materials: In vivo imaging system, dissection tools, NIR-II fluorophore, homogenizer, near-infrared fluorescence (NIRF) plate reader. Procedure:

• In Vivo Imaging: Administer the NIR-II probe intravenously to the animal. Acquire longitudinal in vivo images at defined time points (e.g., 1, 4, 24, 48 h) under consistent anesthesia and positioning.
• Euthanasia and Dissection: At the terminal time point, euthanize the animal. Perfuse with PBS to remove blood pool signal. Excise target organs (tumor, liver, spleen, kidney, muscle) and weigh them.
• Ex Vivo Measurement: Homogenize each organ. Prepare standard solutions of the probe. Measure fluorescence of homogenates and standards using a NIRF plate reader. Calculate the exact probe mass (ng) per gram of tissue.
• Correction Factor: Plot the ex vivo probe concentration (ng/g) against the mean in vivo fluorescence intensity (counts/sec/mm²) for each organ. Perform linear regression. The slope of this line represents the system- and tissue-specific correction factor to convert in vivo intensity to absolute quantity.

Visualizations

Title: Sources of Confound in Raw NIR-II Signal

Title: Workflow for Artifact Correction in NIR-II Imaging

The Scientist's Toolkit: Research Reagent Solutions

Item	Function in Correction Protocols
Intralipid 20% emulsion	Tissue-mimicking phantom component providing controlled scattering (μs').
India Ink	Tissue-mimicking phantom component providing controlled absorption (μa).
NIR-II Calibration Fluorophores (e.g., IRDye 1500, CH-4T)	Provide stable, known quantum yield signals for phantom studies and system calibration.
Reference NIR-II Dye with Non-Overlapping Spectrum	Used as an internal control for spectral unmixing to isolate probe signal from autofluorescence.
Isoflurane/Oxygen Anesthesia System	Minimizes voluntary animal motion; allows for respiratory gating.
Physiological Monitoring Unit (Respiratory Pad)	Provides real-time respiratory signal for triggered, motion-gated image acquisition.
Tissue Homogenization Kit (Beads, Buffer)	For homogenizing excised organs to correlate ex vivo probe concentration with in vivo signal.
Fluorescence Plate Reader (NIR-II capable)	Precisely quantifies fluorophore concentration in tissue homogenates and standard solutions.
Image Registration Software (e.g., FIJI/ImageJ with TurboReg/StackReg)	Open-source tools for performing post-hoc rigid/non-rigid motion correction on image stacks.

Optimizing Injection Dose, Timing, and Imaging Windows

This document provides application notes and protocols for optimizing the in vivo administration and imaging of NIR-II (1000-1700 nm) fluorescent probes. This work is integral to the broader thesis on establishing standardized, reliable protocols for NIR-II fluorescent probes to enable quantitative, deep-tissue biomarker detection in preclinical research, directly impacting drug development and therapeutic monitoring.

Table 1: Optimization Variables and Impact on Signal-to-Noise Ratio (SNR)

Variable	Typical Range (Small Animal)	Primary Impact on Imaging	Key Consideration
Probe Dose	0.1 - 10 mg/kg (varies by probe)	Directly influences target occupancy & background.	High dose may saturate target or increase non-specific background. Low dose may yield insufficient signal.
Injection Route	IV (tail vein, retro-orbital), IP, SC	Affects pharmacokinetics, bioavailability, and first-pass metabolism.	IV provides rapid, systemic distribution. IP/SC allow slower absorption for prolonged imaging windows.
Pre-imaging Circulation Time	1 min - 48 hrs	Allows for probe clearance from blood pool and binding to target.	Critical for target-to-background ratio (TBR). Must be empirically determined for each probe-target pair.
Imaging Window Duration	Minutes to hours post-injection	Defines the period for reliable data acquisition.	Must capture peak TBR, which is a balance of target accumulation and systemic clearance.
Anesthesia	Isoflurane (1-3%), Ketamine/Xylazine	Impacts heart rate, perfusion, and probe biodistribution.	Must be consistent across studies. Isoflurane allows for quick recovery for longitudinal imaging.

Table 2: Example Protocols for Common NIR-II Probe Classes

Probe Class	Target	Recommended Dose (IV)	Optimal Circulation Time	Peak Imaging Window	Rationale
Non-targeted (e.g., SWCNTs, Ag2S QDs)	Vascular/ Passive Accumulation (EPR)	2-5 mg/kg	1-5 min post-injection	0-30 min	Relies on blood pool circulation or rapid extravasation in leaky vasculature (tumors).
Antibody-Conjugated	Cell Surface Receptor (e.g., HER2)	1-2 nmol (≈ 1-2 mg/kg)	24 - 48 hours	24 - 72 hours	Requires long time for blood clearance and high-affinity binding to reach maximal TBR.
Small Molecule / Peptide	Enzymatic Activity or Receptor	2-10 nmol/kg	1 - 6 hours	1 - 12 hours	Faster pharmacokinetics than antibodies; optimal window balances binding and clearance.
Activatable (Smart Probe)	Protease Activity (e.g., MMP)	5-10 mg/kg	4 - 24 hours	6 - 48 hours	Requires time for probe accumulation at site (e.g., tumor), enzymatic cleavage, and clearance of unactivated probe.

Detailed Experimental Protocols

Protocol 1: Determining Optimal Dose and Circulation Time

Objective: To identify the probe dose and post-injection circulation time that yield the maximum Target-to-Background Ratio (TBR) for a novel NIR-II probe targeting a tumor biomarker.

Materials: See "Scientist's Toolkit" below. Procedure:

• Animal Model Preparation: Implant tumor cells (e.g., 4T1, U87MG) subcutaneously in nude mice (n=4-5 per group). Allow tumors to grow to 100-300 mm³.
• Probe Administration:
  • Prepare sterile solutions of the NIR-II probe at varying concentrations in PBS or saline (e.g., 0.5, 1.0, 2.0, 5.0 mg/kg).
  • Randomize tumor-bearing mice into dose groups.
  • Inject each mouse intravenously (tail vein) with the assigned probe dose. Record exact injection volume and time.
• Longitudinal Imaging:
  • Anesthetize mice using 2% isoflurane in oxygen.
  • Image mice at multiple time points post-injection (e.g., 5 min, 30 min, 1h, 2h, 4h, 6h, 24h, 48h) using the NIR-II imaging system.
  • Imaging Parameters: Keep constant (Laser power: 100 mW/cm², Exposure: 100-500 ms, Filter: 1000 nm LP or 1500 nm SP).
  • Acquire both fluorescence and white-light reference images.
• Image Analysis:
  • Using ROI software, quantify mean fluorescence intensity (MFI) in the tumor (T) and a contralateral background tissue (B).
  • Calculate TBR = MFI(T) / MFI(B) for each mouse at each time point.
  • Plot TBR vs. Time for each dose group.
• Determination of Optima:
  • The optimal dose is the lowest dose that produces a statistically significant TBR plateau or peak, minimizing non-specific background.
  • The optimal circulation/imaging window is the time point(s) at which the maximal TBR is achieved for the optimal dose.

Protocol 2: Multi-Modal Imaging Window Alignment

Objective: To align the NIR-II imaging window with complementary imaging modalities (e.g., MRI, PET) for longitudinal, multi-parametric studies.

Procedure:

• Baseline Anatomical Scan: Prior to probe injection, perform an MRI scan to acquire high-resolution anatomical references.
• Timeline Synchronization:
  • Inject the NIR-II probe at the predetermined optimal dose (from Protocol 1).
  • At the optimal pre-imaging time, anesthetize the mouse and transfer it to the multi-modal imaging bed/setup.
  • Perform NIR-II fluorescence imaging first to minimize signal decay during setup for other modalities.
• Sequential Multi-Modal Acquisition:
  • Immediately following NIR-II, acquire a micro-CT or T2-weighted MRI scan (≈10-15 min) for co-registration.
  • For PET alignment, co-inject or pre-inject a radiotracer with a compatible half-life (e.g., ¹⁸F, ≈110 min). The imaging session should be scheduled so that the peak uptake windows of both probes overlap.
• Data Co-registration:
  • Use fiduciary markers or anatomical landmarks visible across modalities.
  • Employ software (e.g., AMIRA, 3D Slicer) to spatially align NIR-II fluorescence maps with anatomical (MRI/CT) and functional (PET) datasets.

The Scientist's Toolkit: Research Reagent Solutions

Item	Function & Rationale
NIR-II Fluorescent Probe	The core reagent. Provides emission >1000 nm for reduced tissue scattering/autofluorescence and enhanced penetration depth.
Sterile PBS/Saline	Standard vehicle for probe formulation. Ensures biocompatibility and consistent injection volume.
Isoflurane Vaporizer System	Preferred method for anesthesia. Allows rapid induction/recovery, crucial for longitudinal studies and maintaining physiological stability.
Tail Vein Restrainer & Heater	Facilitates consistent and reliable intravenous injection by dilating the tail veins.
NIR-II Imaging System	Includes a 808 nm or 980 nm laser for excitation, InGaAs or SWIR camera for detection, and long-pass filters to block excitation light.
Image Analysis Software (e.g., ImageJ, LI-COR, Living Image)	For drawing ROIs, quantifying fluorescence intensity, and calculating metrics like TBR and SNR.
Matrigel / Tumor Cell Line	For establishing subcutaneous tumor xenograft models, a common testbed for probe validation.
Blackout Enclosure	Essential for blocking ambient light during imaging to prevent background noise in the sensitive NIR-II range.

Visualizations

Ensuring Probe Stability and Preventing Photobleaching During Long-Term Studies

Within the broader thesis on NIR-II fluorescent probe protocols for deep tissue biomarker detection, this document addresses the critical challenges of probe stability and photobleaching. Long-term imaging studies, essential for monitoring disease progression or therapeutic efficacy in vivo, are often compromised by signal decay. These Application Notes and Protocols provide methodologies to characterize, mitigate, and control these destabilizing factors, ensuring reliable quantitative data.

Key Degradation Pathways & Quantitative Stability Metrics

Photobleaching and instability arise from specific molecular pathways. Quantitative characterization is the first step toward mitigation.

Table 1: Primary Degradation Pathways of NIR-II Probes

Pathway	Mechanism	Primary Consequence	Most Susceptible Probe Classes
Photobleaching	Irreversible photochemical destruction of fluorophore upon repeated excitation.	Exponential signal decay over time.	Organic dyes (e.g., IR-26, CH-4T), some semiconductor polymers.
Aggregation-Caused Quenching (ACQ)	High-concentration or hydrophobic-driven aggregation leading to non-radiative decay.	Loss of brightness in situ; unreliable quantification.	Most organic fluorophores.
Chemical Degradation	Reaction with reactive oxygen species (ROS) or enzymatic cleavage in biological milieu.	Permanent loss of fluorescence; altered biodistribution.	Aqueous dispersions of single-walled carbon nanotubes (SWCNTs), some dye-bioconjugates.
Deshelling/Decomposition	Loss of stabilizing surface coating (e.g., PEG, lipids) or disintegration of nanoparticle matrix.	Increased clearance, altered targeting, aggregation.	Inorganic nanoparticles (quantum dots, rare-earth doped).

Table 2: Key Quantitative Stability Metrics

Metric	Definition & Measurement	Target Threshold for Long-Term Studies
Photobleaching Half-Life (t₁/₂)	Time for fluorescence intensity to decay to 50% under constant, defined illumination. Measured in vitro in relevant buffer.	> 30 minutes under typical imaging flux (e.g., 100 mW/cm² at 808 nm).
Quantum Yield (QY) Retention	Percentage of initial QY retained after X hours in biological fluid (e.g., serum, plasma) at 37°C.	> 80% QY retention after 24 hrs in 50% serum.
Hydrodynamic Diameter (Dₕ) Stability	Change in Dₕ (via DLS) after incubation in biological medium. Indicates aggregation or deshelling.	ΔDₕ < 20% after 48 hrs in PBS or serum.
Targeting Ligand Integrity	Percentage of functional ligand remaining conjugated after incubation, measured via HPLC or binding assay.	> 90% functional ligand retention after 24 hrs in vitro.

Diagram 1: NIR-II Probe Degradation Pathways (84 characters)

Experimental Protocols for Stability Assessment

Protocol 3.1: In Vitro Photobleaching Half-Life (t₁/₂) Measurement

Objective: Quantify photostability under standardized illumination. Materials: Probe solution in PBS/1% BSA, NIR-II spectrometer or imaging system with 808 nm laser, quartz cuvette/imaging chamber, power meter. Procedure:

• Prepare probe at a standard working concentration (e.g., 10 µg/mL for nanoparticles, 5 µM for dyes).
• Place sample in system. Measure initial fluorescence intensity (I₀) with a very low power, single pulse.
• Initiate constant illumination at a defined power density (e.g., 100 mW/cm² at 808 nm). Critical: Ensure sample is mixed or laser is defocused to avoid local heating.
• Acquire fluorescence intensity (I) at regular intervals (e.g., 30 sec) for 30-60 minutes.
• Plot I/I₀ vs. time. Fit curve to a single-exponential decay: I(t) = I₀ * exp(-kt)*.
• Calculate t₁/₂ = ln(2)/k.

Protocol 3.2: Serum Stability & Quantum Yield Retention

Objective: Assess probe integrity in biologically relevant medium. Materials: Probe stock, fetal bovine serum (FBS), PBS, HPLC system with fluorescence detector, integrating sphere for QY. Procedure:

• Incubate probe in 50% FBS/PBS at 37°C. Aliquot at t=0, 2, 6, 24, 48 hrs.
• For QY Retention: Dilute aliquots in PBS to equal absorbance (<0.1). Measure fluorescence spectra. Compare integrated intensity against a NIR-II reference dye with known QY (e.g., IR-26 in DCE). Calculate QY for each time point.
• For Chemical Integrity: Analyze aliquots via size-exclusion chromatography (SEC-HPLC) with fluorescence detection. Monitor shift in elution peak (indicates aggregation) or appearance of new peaks (indicates degradation byproducts).

Protocol 3.3: In Vivo Longitudinal Stability Workflow

Objective: Decouple biological clearance from photobleaching in live studies. Materials: Animal model, NIR-II imager, isoflurane anesthesia system. Procedure:

• Administer probe intravenously. Acquire a high-signal baseline image at t=1h post-injection using minimal laser power/exposure.
• At each subsequent imaging time point (e.g., 6, 24, 48, 72h): a. Acquire image with identical parameters as baseline. b. Administer a tiny "top-up" dose (e.g., 10% of original) of the same probe. c. Image the same field immediately after top-up.
• Analysis: The signal after top-up reveals the maximum possible signal at that time point, controlled for clearance and biodistribution. The difference between pre-top-up and post-top-up signal estimates the fraction of active, unbleached probe remaining at the site.

Diagram 2: In Vivo Stability Workflow (82 characters)

Stabilization Strategies & Formulation Protocol

Table 3: Stabilization Strategies and Their Applications

Strategy	Method	Mechanism	Best For
Oxygen Scavenging	Co-formulate with Trolox, ascorbic acid, or use enzymatic systems (e.g., PCA/PCD).	Reduces ROS generated during excitation.	All aqueous probe formulations for in vitro or ex vivo imaging.
Robust Surface Engineering	Use dense PEGylation, lipid-PEG coatings, or cross-linked polymer shells.	Prevents opsonization, aggregation, and deshelling.	Inorganic nanoparticles (QDs, rare-earth), SWCNTs.
Aggregation-Induced Emission (AIE)	Employ AIEgens or design probes with bulky side groups.	Suppresses ACQ by restricting intramolecular motion.	Organic dye aggregates and polymeric probes.
Pulsed Illumination & Lower Power	Use time-gated detection synchronized with pulsed lasers.	Reduces total photon flux and heat deposition on probe.	All in vivo long-term imaging studies.
Cryo-Formulation for Storage	Lyophilize with cryoprotectants (e.g., trehalose, sucrose).	Preserves shell integrity and prevents aggregation upon reconstitution.	Long-term storage of all probe types.

Protocol 4.1: Formulating a Stabilized, Ready-to-Inject NIR-II Probe (SWCNT Example)

Objective: Prepare a serum-stable, photoresistant SWCNT probe for longitudinal imaging. Materials: Raw SWCNTs, phospholipid-PEG (PL-PEG, e.g., DSPE-mPEG2000), Pluronic F127, sodium cholate, Trolox, probe tip sonicator, centrifuge, 100 kDa centrifugal filter. Procedure:

• Dual-Coating Dispersion: In 1 mL PBS, combine 1 mg SWCNTs, 2 mg PL-PEG, 2 mg Pluronic F127, and 1 mg sodium cholate.
• Sonication: Sonicate on ice at 40% amplitude for 30 min (pulse 5s on/5s off).
• Ultracentrifugation: Centrifuge at 20,000 g for 30 min. Collect supernatant containing individually coated nanotubes.
• Purification & Stabilizer Addition: Concentrate using a 100 kDa filter. Wash 3x with PBS to remove free surfactants. Resuspend in PBS containing 1 mM Trolox.
• Sterilization: Pass through a 0.22 µm sterile filter. Aliquot and store at 4°C protected from light. Characterize Dₕ (target: 30-100 nm), NIR-II fluorescence QY, and perform Protocol 3.2.

The Scientist's Toolkit: Key Reagent Solutions

Table 4: Essential Research Reagents for NIR-II Probe Stability

Item/Reagent	Function in Stability Studies	Example/Notes
Phospholipid-PEG (PL-PEG)	Provides stealth coating, prevents protein adsorption & aggregation. Critical for in vivo stability.	DSPE-mPEG2000; vary PEG length for circulation time.
Oxygen Scavengers	Mitigate photobleaching by quenching reactive oxygen species (ROS) generated during imaging.	Trolox, Ascorbic Acid, Protocatechuic Acid/Protocatechuate-3,4-Dioxygenase (PCA/PCD) system.
Size-Exclusion HPLC Columns	Analyze probe integrity, detect aggregation or degradation byproducts in serum/buffer over time.	TSKgel columns (e.g., TSKgel G4000SWXL) with fluorescence detection.
Reference NIR-II Dyes	Essential for quantifying Quantum Yield (QY) retention in stability assays.	IR-26 (in 1,2-dichloroethane), IR-1061. Handle as non-aqueous benchmarks.
Cryoprotectants	Preserve probe formulation during lyophilization for long-term storage, preventing aggregation upon reconstitution.	Trehalose, Sucrose, typically at 5-10% w/v in formulation buffer.
Power-Density-Calibrated Laser Source	Enables standardized, reproducible photobleaching measurements. Critical for comparing probes.	808 nm or 980 nm laser with integrated power meter or pre-calibrated output.
Serum/Plasma (e.g., FBS)	Biologically relevant medium for pre-clinical stability testing.	Use consistent lot numbers for comparable experiments.

Benchmarking Performance: Validating Specificity and Comparing NIR-I vs. NIR-II Probes

Within the broader thesis on NIR-II fluorescent probe protocols for deep tissue biomarker detection, this document details the critical ex vivo validation phase. Following in vivo NIR-II imaging, systematic correlation of fluorescence signals with gold-standard histopathological analysis and precise biomarker quantification is essential to confirm probe specificity, accuracy, and biological relevance. This application note provides standardized protocols for this validation workflow.

Key Research Reagent Solutions

The following table lists essential materials for successful ex vivo validation.

Item	Function & Explanation
NIR-II Fluorescent Probe	The targeting agent (e.g., antibody-, peptide-, or small molecule-conjugated) emitting light in the 1000-1700 nm range for deep tissue penetration and high signal-to-background ratio.
Optimal Cutting Temperature (OCT) Compound	A water-soluble embedding medium used for freezing and cryo-sectioning tissues, preserving fluorescence and antigen integrity.
Phosphate-Buffered Saline (PBS)	An isotonic buffer used for washing tissues and sections to remove unbound probe and reduce non-specific background.
Paraformaldehyde (4%, PFA)	A cross-linking fixative used to preserve tissue morphology while retaining a degree of antigenicity for subsequent staining.
Antibody for Immunohistochemistry (IHC)	A primary antibody targeting the biomarker of interest, used for classical chromogenic detection and correlation with NIR-II signal.
Mounting Medium with DAPI	A medium for sealing coverslips, containing a nuclear counterstain (4',6-diamidino-2-phenylindole) for histological orientation.
Fluorophore-conjugated Secondary Antibody	For immunofluorescence (IF) co-localization studies, conjugated to a visible-range fluorophore (e.g., Cy3, FITC).
Digital Slide Scanner	Equipment capable of scanning histological slides at high resolution, including brightfield (IHC) and fluorescence (NIR-II/IF) channels.
Image Co-Registration Software	Software (e.g., ImageJ/FIJI with plugins, QuPath) to accurately align and overlay NIR-II fluorescence images with histology images.
Biomarker Quantification Software	Software for quantifying biomarker expression levels from IHC (e.g., H-score, positive pixel count) or fluorescence intensity from NIR-II/IF images.

Experimental Protocols

Protocol: Tissue Harvesting and Preparation Post NIR-II Imaging

Objective: To preserve the in vivo NIR-II fluorescence signal and tissue morphology for histology.

• Euthanize the animal per approved protocol at the desired time point post-probe injection.
• Perfuse the animal transcardially with 20-30 mL of ice-cold 1x PBS to clear blood and unbound circulating probe.
• Excise the target organ(s) and regions of interest (ROIs) identified during in vivo imaging.
• For fluorescence preservation: Snap-freeze ROI pieces in OCT compound using a dry ice/isopentane bath or liquid nitrogen. Store at -80°C.
• For optimal morphology: Fix ROI pieces in 4% PFA for 24-48 hours at 4°C, then transfer to 30% sucrose for cryoprotection before OCT embedding.
• Section tissues at 5-10 µm thickness using a cryostat. Collect serial sections on charged slides for H&E, IHC, and direct NIR-II fluorescence scanning.

Protocol: Histological Correlation Workflow

Objective: To correlate the spatial distribution of the NIR-II signal with standard histology and biomarker expression.

• Slide Scanning:
  • Scan the unstained tissue section using a NIR-II compatible imaging system or a scanner with a suitable spectral detector to capture the ex vivo probe fluorescence. Record exposure settings.
  • Stain the adjacent serial section with Hematoxylin and Eosin (H&E) for general morphology.
  • Perform IHC (e.g., DAB chromogen) or immunofluorescence (IF) for the target biomarker on another adjacent section.
  • Digitally scan all H&E and IHC/IF slides using a brightfield/fluorescence slide scanner.
• Image Co-Registration:
  • Import all digital images into co-registration software.
  • Use the tissue outline and distinct morphological features (e.g., blood vessels, ducts) as fiducial markers.
  • Apply affine or elastic transformation algorithms to align the NIR-II fluorescence image precisely with the H&E and IHC/IF images from adjacent sections.
• Analysis:
  • Visually and quantitatively assess the spatial overlap between the NIR-II signal and the IHC/IF staining pattern.
  • Calculate metrics like Pearson's or Mander's correlation coefficients for co-localization (for IF).

Protocol: Quantitative Biomarker Analysis

Objective: To derive quantitative metrics of biomarker expression from both IHC and NIR-II fluorescence.

• IHC Quantification (H-Score Method):
  • Within defined ROIs on the IHC digital slide, score the staining intensity (0: none, 1+: weak, 2+: moderate, 3+: strong) and the percentage of cells at each intensity.
  • Calculate the H-Score: H-Score = Σ (1 * %1+ cells) + (2 * %2+ cells) + (3 * %3+ cells). Possible range is 0-300.
• NIR-II Signal Quantification:
  • On the co-registered, raw NIR-II fluorescence image, define the identical ROI used for IHC analysis.
  • Measure the mean fluorescence intensity (MFI), total fluorescence, or integrated density within the ROI.
  • Subtract the MFI from a background ROI (e.g., unstained tissue or isotype control probe section) to obtain the specific signal.
• Correlation Analysis:
  • Plot the quantitative IHC metric (e.g., H-Score) against the quantitative NIR-II signal (e.g., Background-Subtracted MFI) for all analyzed ROIs/samples.
  • Perform linear regression analysis and report the correlation coefficient (R²).

Data Presentation

Table 1: Exemplary Data from Ex Vivo Validation of a NIR-II Probe Targeting EGFR in a Xenograft Model

Sample ID	Tumor Region	IHC H-Score (Target)	NIR-II MFI (a.u.)	Background MFI (a.u.)	Specific NIR-II MFI (a.u.)	Co-localization Coefficient (vs. IF)
XG1	Core	245	12,850	1,200	11,650	0.89
XG1	Invasive Edge	280	15,340	1,050	14,290	0.92
XG2	Core	80	3,450	980	2,470	0.78
XG2	Necrotic Zone	15	1,500	1,300	200	0.12
Control (PBS)	Core	10	1,100	1,050	50	0.08

Table 2: Summary of Correlation Statistics Across a Study Cohort (n=10 Tumors)

Correlation Pair	Pearson's r	R²	p-value
Specific NIR-II MFI vs. IHC H-Score	0.94	0.88	<0.0001
NIR-II Tumor-to-Muscle Ratio vs. IHC H-Score	0.91	0.83	<0.0001

Visualizations

Title: Ex Vivo Histology Correlation Workflow

Title: Probe Binding and Validation Pathway

Within the burgeoning field of in vivo optical bioimaging, the development and application of NIR-II (1000-1700 nm) fluorescent probes represent a paradigm shift for deep-tissue biomarker detection. The central thesis posits that optimizing the trio of interrelated metrics—Penetration Depth, Resolution, and Contrast—is critical for translating NIR-II imaging from a research tool into a robust protocol for preclinical research and drug development. This application note details the quantitative comparison of these metrics and provides standardized experimental protocols for their validation.

Quantitative Metrics Comparison

Table 1: Core Performance Metrics of NIR-II versus Traditional Imaging Windows

Metric	NIR-I Window (700-900 nm)	NIR-II Window (1000-1700 nm)	Key Determinants
Penetration Depth	~1-3 mm in tissue	~3-10 mm in tissue	Reduced scattering & minimal autofluorescence in NIR-II.
Resolution	~10-20 µm (in vivo)	~5-15 µm (in vivo, sub-diffraction limit possible)	Lower scattering enables higher spatial fidelity.
Contrast (Signal-to-Background Ratio - SBR)	Moderate (High autofluorescence)	High (>10:1 common)	Negligible tissue autofluorescence beyond 1100 nm.
Tissue Absorption Coefficient	Relatively High	Significantly Lower	Water absorption peaks influence optimal sub-windows (e.g., 1500-1700 nm).

Table 2: Impact of Probe Properties on Key Metrics

Probe Property	Penetration Depth	Resolution	Contrast	Rationale
Emission Max (λem)	++ (Longer λ > 1200 nm)	+	++	Further reduction in scattering/absorption.
Quantum Yield (QY)	-	-	++	Directly improves signal intensity for a given concentration.
Brightness (ε x QY)	+	+	+++	Crucial for detecting low-abundance biomarkers.
Hydrodynamic Diameter	-- (Large nanoparticles)	-- (if aggregation)	Variable	Size affects biodistribution and clearance routes.
Targeting Specificity	-	-	++++	Drives biomarker-specific accumulation, defining functional contrast.

Experimental Protocols

Protocol 1: System Characterization for Metric Quantification

Objective: Calibrate the NIR-II imaging system to standardize measurements of penetration, resolution, and contrast. Materials: NIR-II imaging system, Tungsten halogen lamp, NIR-II reflectance standards, USAF 1951 resolution target, capillary tubes. Procedure:

• Flat-Field Correction: Acquire an image of a uniform NIR-II reflectance standard. Use this to generate a correction matrix for pixel-to-pixel intensity variance.
• Resolution Calibration: Image the USAF target embedded in a tissue-simulating phantom (e.g., 1% Intralipid). Measure the smallest resolvable group element to define the system's spatial resolution under scattering conditions.
• Depth Sensitivity: Prepare a phantom with a fluorescent tube at known, increasing depths (0-10 mm). Image and plot signal intensity vs. depth to characterize the system's depth-dependent signal attenuation.

Protocol 2:In VivoValidation of a NIR-II Probe for Tumor Biomarker Detection

Objective: Quantify the penetration depth, resolution, and contrast achieved by a targeted NIR-II probe in a live tumor model. Materials: Athymic nude mice, subcutaneous xenograft tumor model, targeted NIR-II probe (e.g., antibody-conjugated single-walled carbon nanotubes or Ag₂S quantum dots), isotype control probe, NIR-II fluorescence imager. Procedure:

• Probe Administration: Via tail vein, inject the targeted NIR-II probe (experimental group, n≥5) or an equivalent dose of the isotype control probe (control group) into tumor-bearing mice.
• Longitudinal Imaging: Anesthetize mice and image at t = 1, 4, 8, 12, 24, and 48 hours post-injection using consistent imaging parameters (laser power, exposure time, filters).
• Data Analysis:
  • Contrast (SBR): Calculate Signal-to-Background Ratio as (Mean Tumor Signal) / (Mean Contralateral Tissue Signal).
  • Penetration Assessment: Observe the clarity of deep-tissue anatomical features (e.g., deep vasculature, spine) in the images.
  • Resolution: Measure the full-width half maximum (FWHM) of intensity line profiles across small subcutaneous vessels to quantify achievable resolution.
• Ex Vivo Validation: Terminate study, collect tumors and major organs for ex vivo imaging and histology to correlate fluorescence with biomarker expression.

Visualizations

NIR-II Probe Workflow & Metrics

NIR-I vs NIR-II Light-Tissue Interaction

The Scientist's Toolkit: Essential Research Reagents & Materials

Table 3: Key Research Reagent Solutions for NIR-II Imaging

Item	Function in Protocol	Example/Notes
Targeted NIR-II Probe	Active targeting component for biomarker-specific contrast.	Antibody-conjugated Ag₂S QDs, peptide-labeled single-walled carbon nanotubes (SWCNTs).
Isotype Control Probe	Critical negative control to distinguish specific vs. non-specific uptake.	Identical nanoparticle conjugated to a non-targeting antibody.
Tissue-Simulating Phantom	System calibration and metric standardization.	1-2% Intralipid for scattering, India ink for absorption.
NIR-II Fluorescence Imager	Detection system with sensitivity in 1000-1700 nm range.	InGaAs or cooled CCD cameras with appropriate long-pass filters.
NIR-II Excitation Source	Light source for probe excitation.	808 nm or 980 nm lasers are common for many probes.
Animal Model with Biomarker	In vivo validation of probe performance metrics.	Subcutaneous or orthotopic xenograft models; genetically engineered models.
Image Analysis Software	Quantification of SBR, resolution (FWHM), and signal kinetics.	Fiji/ImageJ, Living Image, or custom MATLAB/Python scripts.

Within the context of advancing protocols for NIR-II fluorescent probes in deep tissue biomarker detection, a critical operational decision lies in the choice of imaging window. This application note provides a current, data-driven comparison between the traditional NIR-I (700-900 nm) and the emerging NIR-II (1000-1700 nm) imaging windows. The superior performance of NIR-II imaging in penetration depth, spatial resolution, and signal-to-background ratio is revolutionizing in vivo optical imaging for preclinical research and therapeutic development.

Comparative Performance Data

Table 1: Quantitative Comparison of NIR-I vs. NIR-II Imaging Windows

Performance Metric	NIR-I (700-900 nm)	NIR-II (1000-1700 nm)	Key Implications
Optical Penetration Depth	1-3 mm in tissue	5-10 mm in tissue	Enables non-invasive imaging of deep-seated organs and tumors.
Spatial Resolution	~3-5 mm at 3 mm depth	~20-40 μm at 3 mm depth	Allows for detailed microvasculature imaging and precise anatomical localization.
Signal-to-Background Ratio (SBR)	Moderate (limited by tissue autofluorescence & scattering)	High (significantly reduced scattering & autofluorescence)	Improves biomarker detection sensitivity and quantification accuracy.
Tissue Autofluorescence	High (peaks ~700-800 nm)	Negligible (>900 nm)	Drastically lowers background, enhancing contrast for probe signal.
Photon Scattering	High	Reduced by ~λ^-0.2 to λ^-4 dependence	Enables clearer, sharper images through turbid media.
Common Probe Types	ICG, Cy7, Alexa Fluor 790	Organic dyes (e.g., CH-4T), Quantum Dots, Single-Wall Carbon Nanotubes, Lanthanide NPs	Requires dedicated probe synthesis and conjugation protocols.

Experimental Protocols for Comparative Validation

Protocol 3.1: Side-by-SideIn VivoTumor Imaging

Objective: To compare the imaging performance of a dual-emissive probe in both NIR-I and NIR-II windows in a murine tumor model.

Materials:

• Animal Model: Mice with subcutaneously implanted xenograft tumors.
• Probe: A single probe with emissions in both NIR-I (e.g., ~800 nm) and NIR-II (e.g., ~1100 nm) windows (e.g., certain rare-earth-doped nanoparticles or engineered small molecule dyes).
• Imaging Systems: Separate or spectral-filtered NIR-I and NIR-II cameras (e.g., InGaAs detector for NIR-II).
• Anesthesia: Isoflurane/oxygen vaporizer.

Procedure:

• Probe Administration: Inject the probe intravenously via the tail vein at an optimized dose (e.g., 100-200 μL of 100 μM solution).
• Image Acquisition: Anesthetize the mouse and place it in the imaging chamber.
• Time-Course Imaging: Acquire coregistered images at multiple time points post-injection (e.g., 1, 4, 12, 24, 48 h) using both NIR-I and NIR-II channels under identical laser excitation.
• Data Analysis: Quantify the Tumor-to-Background Ratio (TBR) from both channels. Measure the apparent tumor size and vascular features based on image clarity.

Protocol 3.2: Ex Vivo Biodistribution Analysis via Fluorescence Quantification

Objective: To validate in vivo imaging data and quantify probe accumulation in tissues.

Procedure:

• Tissue Harvest: At the terminal time point (e.g., 48 h post-injection), euthanize the mouse. Excise major organs (heart, liver, spleen, lungs, kidneys, tumor) and rinse with PBS.
• Homogenization: Homogenize each tissue sample in a suitable buffer.
• Spectrofluorometric Measurement: Measure the fluorescence intensity of each homogenate using a spectrofluorometer equipped with both NIR-I and NIR-II detection capabilities. Use identical excitation settings.
• Quantification: Generate a biodistribution profile (% Injected Dose per Gram of tissue, %ID/g) for each imaging window and compare correlation.

The Scientist's Toolkit: Essential Research Reagents & Materials

Table 2: Key Reagent Solutions for NIR-II Imaging Protocols

Item	Function/Application	Example/Notes
NIR-II Fluorescent Probes	Biomarker tagging and signal generation.	CH1055-PEG organic dye, Ag2S quantum dots, Er3+-doped nanoparticles. Must be functionalized for targeting.
Targeting Ligands	Confer specificity to biomarkers of interest.	Antibodies (e.g., anti-VEGF, anti-PSMA), peptides (e.g., RGD), or small molecules.
Dialysis Membranes (MWCO)	Purification of conjugated probe-ligand constructs.	Remove unreacted dye and ligands. Choice of MWCO depends on probe size.
Matrix for Phantom Studies	Simulating tissue scattering/absorption for system calibration.	1% Intralipid or agarose phantoms with India ink.
Anesthesia System	Maintain animal immobility and physiological stability during in vivo imaging.	Isoflurane vaporizer with nose cones.
NIR-II Imaging System	Detection of NIR-II photons.	Requires InGaAs or other SWIR camera, appropriate lasers (808 nm, 980 nm), and spectral filters.

Visualized Workflows and Pathways

This Application Note provides a detailed protocol and comparative analysis of major near-infrared window II (NIR-II, 1000-1700 nm) fluorescent probe classes for deep tissue biomarker detection, framed within ongoing thesis research to standardize methodologies in the field.

The NIR-II biological window offers superior imaging depth and resolution compared to visible and NIR-I fluorescence due to reduced scattering and autofluorescence. The development of targeted probes for specific biomarker detection in this window is a critical frontier for non-invasive diagnostics and therapeutic monitoring. This document evaluates four primary probe classes: Organic Dyes, Quantum Dots, Single-Walled Carbon Nanotubes (SWCNTs), and Rare-Earth-Doped Nanoparticles (RENPs).

Quantitative Comparison of NIR-II Probe Classes

Table 1: Core Photophysical & Functional Properties

Probe Class	Typical Emission Range (nm)	Quantum Yield Range	Excitation Source	Typical Hydrodynamic Size (nm)	Key Advantages	Primary Limitations
Organic Dyes	1000-1300	0.1-5%	808 nm, 980 nm	1-5	Rapid renal clearance, good biocompatibility, modular synthesis.	Low quantum yield, modest brightness, moderate photostability.
Quantum Dots	1100-1600	5-15%	808 nm, 980 nm	5-15 (with coating)	High brightness, tunable emission, good photostability.	Potential heavy metal toxicity, larger size limits clearance, batch variability.
SWCNTs	1000-1600	0.1-1%	660, 785, 808 nm	100-500 (length)	Exquisite photostability, inherent chirality-based sensing, tissue penetration >3 mm.	Low quantum yield, polydisperse size, complex functionalization.
Rare-Earth NPs	1525, 1550, 1625 (etc.)	<1% (in water)	808, 980, 1530 nm	20-100	Sharp emission peaks, long luminescence lifetimes, no photoblinking.	Low aqueous QY, often require high-power excitation, complex synthesis.

Table 2: Functionalization & Biocompatibility Profile

Probe Class	Common Targeting Ligands	Typical Bioconjugation Chemistry	Clearance Pathway	Reported In Vivo Circulation Half-life
Organic Dyes	Peptides, antibodies, small molecules.	NHS-ester, click chemistry, maleimide.	Renal/Hepatic	Minutes to a few hours.
Quantum Dots	PEG, peptides, antibodies.	EDC/sulfo-NHS, streptavidin-biotin, maleimide.	Reticuloendothelial System (RES)	Hours to days.
SWCNTs	PEG, phospholipids, DNA, antibodies.	PL-PEG functionalization, adsorption, carbodiimide.	RES, some renal for ultrashort tubes.	Hours to days.
Rare-Earth NPs	PEG, silica shells, targeting peptides.	Layer-by-layer coating, silanization.	Primarily RES	Hours to days.

Experimental Protocols

Protocol 3.1: Standardized In Vitro Characterization of NIR-II Probes

Objective: To uniformly assess the optical properties and specific binding of different NIR-II probe classes.

Materials:

• NIR-II probe stock solutions (Organic Dye-CH1055, Ag2S QD, DNA-SWCNT, NaYF4:Yb,Er,Tm@SiO2 RENP).
• Target-positive (e.g., U87-MG) and target-negative cell lines.
• PBS (pH 7.4), blocking buffer (5% BSA in PBS).
• NIR-II fluorescence spectrometer.
• 808 nm and 980 nm laser sources (power density calibrated).
• InGaAs CCD camera or NIR-II imaging system.
• 96-well black-walled plates.

Procedure:

• Dilution Series: Prepare a 6-point dilution series of each probe in PBS across a concentration range of 0.5-50 µM (dye-equivalent).
• Absorption & Emission Scan: For each dilution, record absorption (700-1100 nm) and emission spectra (900-1700 nm) using the NIR-II spectrometer. Use appropriate excitation lasers (e.g., 808 nm for QDs/SWCNTs, 980 nm for RENPs).
• Brightness Calculation: Calculate brightness as (Absorbance at λ_ex) x (Quantum Yield). Use IR-26 dye in dichloroethane as a QY reference standard (QY=0.5%).
• Cell Binding Assay: Seed cells (5x10^4/well) and culture for 24h. Block with 5% BSA. Incubate with targeted and non-targeted versions of each probe class (10 nM dye-equivalent) for 1h at 37°C. Wash 3x with PBS.
• Imaging & Analysis: Image plates using the NIR-II system with consistent laser power and acquisition time. Quantify mean fluorescence intensity (MFI) per well. Calculate signal-to-background ratio (SBR) as (MFItarget-positive) / (MFItarget-negative).

Protocol 3.2: In Vivo Tumor Imaging in Mouse Models

Objective: To compare the performance of different probe classes in a deep-tissue tumor targeting model.

Materials:

• Tumor-bearing mouse model (e.g., subcutaneous U87-MG xenograft).
• Anesthesia system (isoflurane).
• Tail vein catheter.
• Heated imaging stage.
• NIR-II imaging system with 808 nm and 980 nm lasers.
• Long-pass filters (1000, 1250, 1500 nm).

Procedure:

• Preparation: Anesthetize mouse and place on a 37°C heated stage. Establish tail vein catheter.
• Pre-injection Baseline: Acquire a pre-injection image set (808 nm excitation/1000 nm LP filter; 980 nm excitation/1500 nm LP filter).
• Probe Administration: Inject 100 µL of probe solution via catheter (dose: 2 nmol dye-equivalent for organics/QDs, 10 µg for SWCNTs/RENPs).
• Dynamic Imaging: Acquire image sequences at 1, 5, 15, 30, 60, 120, and 240 minutes post-injection. Maintain consistent imaging parameters.
• Ex Vivo Validation: Euthanize animal, resect tumor and major organs (liver, spleen, kidneys, lungs, heart). Image ex vivo to confirm probe distribution.
• Data Analysis: Draw regions of interest (ROI) over tumor and contralateral muscle. Plot tumor-to-background ratio (TBR) over time. Calculate area under the curve (AUC) for the first 120 minutes for comparison.

Visualization of Pathways and Workflows

Diagram 1: Probe Selection and Optimization Workflow

Diagram 2: Targeted NIR-II Imaging Principle

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Reagents for NIR-II Probe Research

Item	Function	Example Product/Catalog Number
NIR-II Reference Dye (IR-26)	Absolute quantum yield standard in organic solvent for calibration.	Sigma-Aldrich, 546374.
Phosphate Buffered Saline (PBS), 10X	Standard buffer for probe dilution, cell washing, and in vivo injection preparation.	Thermo Fisher, BP3994.
Sulfo-NHS ester reactive dye	For amine-bioconjugation of organic dyes and nanoparticle coatings.	Lumiprobe, 100N.
DSPE-PEG(2000)-Maleimide	Thiol-reactive phospholipid-PEG for functionalizing hydrophobic nanoparticles (QDs, SWCNTs).	Nanocs, PG2-MLML-2k.
Matrigel Matrix	For establishing subcutaneous tumor xenografts in mice.	Corning, 354234.
Isoflurane, USP	Volatile anesthetic for in vivo mouse imaging sessions.	Piramal, NDC 66794-017-25.
Live Cell Imaging Agarose	For immobilizing samples during in vitro NIR-II microscopy.	Invitrogen, A37139.
EDC Hydrochloride	Carbodiimide crosslinker for carboxyl-to-amine conjugation (common for SWCNTs, RENPs).	Thermo Fisher, 22980.
Long-pass Optical Filters (1000, 1250, 1500 nm)	Essential for isolating NIR-II emission from excitation laser light during imaging.	Thorlabs, FELH1000, FELH1250, FELH1500.
96-Well Black/Clear Bottom Plates	For high-throughput in vitro cell-based assays with minimal background fluorescence.	Corning, 3904.

The development and application of Near-Infrared Window II (NIR-II, 1000-1700 nm) fluorescent probes for deep-tissue biomarker detection represent a transformative frontier in biomedical research and drug development. However, the rapid growth of this field has been accompanied by significant variability in reported results, often stemming from inconsistent synthesis protocols, characterization methods, and imaging parameters. This lack of standardization directly impedes reproducibility, hinders meaningful comparison between studies, and delays clinical translation. This document establishes detailed application notes and protocols, framed within a broader thesis on NIR-II probe development, to provide researchers with a standardized framework for synthesizing, characterizing, and utilizing these powerful tools. Adherence to these best practices is critical for generating robust, comparable, and reproducible data that can accelerate scientific discovery and therapeutic innovation.

Application Note 1: Standardized Synthesis & Characterization of Organic NIR-II Fluorophores (e.g., CH1055-derivative probes)

Objective: To provide a reproducible protocol for the synthesis, purification, and core characterization of a benchmark small-molecule organic NIR-II fluorophore, establishing baseline metrics for the field.

Research Reagent Solutions & Essential Materials

Item	Function	Example (Supplier/Cat. No.)
CH1055-PEG5k-COOH	Core NIR-II fluorophore scaffold, water-solubilized via PEGylation and functionalized for bioconjugation.	Lumiprobe, #C960
EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide)	Carboxyl group activator for amide bond formation in bioconjugation.	Thermo Fisher, #PG82079
Sulfo-NHS (N-Hydroxysulfosuccinimide)	Stabilizes the EDC-activated ester intermediate, improving conjugation efficiency in aqueous buffers.	Thermo Fisher, #24510
PD-10 Desalting Columns	For rapid buffer exchange and removal of excess small-molecule reagents post-conjugation.	Cytiva, #17085101
Size Exclusion Chromatography (SEC) HPLC System	High-resolution purification of conjugated probe from aggregates and unreacted components.	Agilent 1260 Infinity II
Zetasizer Ultra	Measures hydrodynamic diameter and zeta potential, critical for predicting in vivo behavior.	Malvern Panalytical
Fluorescence Spectrometer with NIR Detector	Measures emission spectra, quantum yield (requires reference), and brightness in the NIR-II window.	Edinburgh Instruments FS5
NIR-II Imaging System	In vitro and in vivo validation of probe performance.	SuNIR (Suzhou NIR-Optics), InGaAs camera-based system

Experimental Protocol

Part A: Conjugation to Targeting Ligand (e.g., Anti-EGFR Antibody)

• Activation of Fluorophore: Dissolve CH1055-PEG5k-COOH (1 mg, ~40 nmol) in 200 µL of anhydrous DMSO. Prepare a fresh solution of EDC (0.5 mg in 50 µL MES buffer, 0.1 M, pH 6.0) and Sulfo-NHS (1.5 mg in 50 µL of the same MES buffer). Add the EDC and Sulfo-NHS solutions to the fluorophore solution. Vortex and react at room temperature for 20 minutes with gentle shaking.
• Antibody Preparation: Simultaneously, buffer-exchange the targeting antibody (e.g., Cetuximab, 4 mg, ~27 nmol) into carbonate buffer (0.1 M, pH 8.5) using a PD-10 column to remove amine-containing stabilizers.
• Conjugation: Add the activated fluorophore-DMSO solution dropwise to the antibody solution with gentle vortexing. The final DMSO concentration should be <10%. React for 2 hours at room temperature in the dark.
• Purification: Pass the reaction mixture through a PD-10 column equilibrated with 1x PBS (pH 7.4) to remove unreacted small molecules. Further purify the main fraction by SEC-HPLC (e.g., TSKgel G3000SW column) to isolate monomeric antibody-probe conjugate from aggregates and free antibody.
• Characterization:
  • Degree of Labeling (DoL): Measure absorbance at 280 nm (protein) and the fluorophore's peak (e.g., 780 nm for CH1055). Use molar extinction coefficients to calculate the DoL (target DoL: 3-5).
  • Size and Charge: Dilute purified conjugate in PBS. Analyze hydrodynamic diameter via Dynamic Light Scattering (DLS) and surface charge via zeta potential using a Zetasizer. Record values in Table 1.

Part B: Core Photophysical Characterization

• Absorbance & Emission Spectra: Dilute the purified probe conjugate in PBS to an absorbance <0.1 at the excitation peak. Record the UV-Vis-NIR absorption spectrum (600-900 nm). For emission, excite at the optimal wavelength (e.g., 785 nm) and collect the fluorescence spectrum from 900-1700 nm using a spectrometer equipped with a liquid N2-cooled InGaAs detector.
• Quantum Yield (QY) Determination: Use a standardized reference (e.g., IR-26 dye in 1,2-dichloroethane, QY = 0.05%) following established procedures. Calculate the absolute QY of the new probe using integrated emission intensities and corrected absorbance values. Record all data in Table 1.

Data Presentation: Core Probe Characterization

Table 1: Standardized Characterization Data for [Probe Name: e.g., CH1055-cetuximab]

Parameter	Method	Result	Target Benchmark
Degree of Labeling (DoL)	UV-Vis-NIR Absorbance	4.2 ± 0.3	3.0 - 5.0
Hydrodynamic Diameter	Dynamic Light Scattering	15.8 ± 1.2 nm	Monomeric peak >95%
Zeta Potential	Electrophoretic Light Scattering	-12.5 ± 2.1 mV	Negative surface charge
Absorption Peak (λ_abs)	UV-Vis-NIR Spectroscopy	785 nm	N/A
Emission Peak (λ_em)	NIR Fluorescence Spectroscopy	1055 nm	N/A
Quantum Yield (Φ)	Relative to IR-26	0.8% ± 0.1%	>0.5% in aqueous buffer
Brightness (ε × Φ)	Calculated	~120 M⁻¹cm⁻¹	Maximize

Title: Standardized NIR-II Probe Development Workflow

Application Note 2: Quantitative In Vivo Imaging Protocol for Tumor Biomarker Detection

Objective: To define a standardized imaging protocol for assessing probe performance in live animal models, ensuring quantitative comparability across labs.

Experimental Protocol

• Animal Model Preparation:

  • Use immunodeficient mice (e.g., BALB/c nude) bearing subcutaneous xenografts (e.g., U87MG for EGFR). Tumor volume should be 100-300 mm³ at the time of imaging.
  • Anesthetize mouse using isoflurane (2-3% for induction, 1-2% for maintenance) in oxygen.
  • Depilate the tumor and surrounding torso region completely to minimize NIR signal attenuation/scattering from hair.

• Pre-Imaging Baseline:

  • Place the anesthetized mouse in the NIR-II imaging system, maintaining body temperature at 37°C.
  • Acquire a pre-injection background image using the same parameters planned for the experiment (Exposure: 100-300 ms, Laser Power: 80-100 mW/cm² @ 808 nm, Filter: 1000 nm long-pass). Save this image for background subtraction.

• Probe Administration & Image Acquisition:

  • Administer the purified probe conjugate via tail vein injection at a standardized dose (e.g., 100 µL of 100 µM solution in PBS, ~2 nmol per mouse).
  • Acquire a time-series of images at defined post-injection timepoints (e.g., 1, 3, 5, 10, 30, 60, 120, 240 minutes). Crucially, maintain identical mouse positioning, laser power, exposure time, and camera settings throughout the series.

• Image Processing & Quantification (Standardized):

  • Background Subtraction: Subtract the pre-injection image from all subsequent images using the imaging system's software or ImageJ.
  • Region of Interest (ROI) Definition: Draw identical-area ROIs over the tumor, a contralateral muscle area (background), and a major vessel (e.g., caudal artery) if visible.
  • Signal Calculation: For each ROI and timepoint, calculate the mean signal intensity (counts per pixel).
  • Key Metrics Calculation:
    • Tumor-to-Background Ratio (TBR): = (Mean Tumor Intensity) / (Mean Muscle Intensity).
    • Signal-to-Noise Ratio (SNR): = (Mean Tumor Intensity - Mean Muscle Intensity) / (Standard Deviation of Muscle Intensity).
    • Area Under the Curve (AUC) for Tumor and Muscle ROI over the imaging period.

Data Presentation: In Vivo Imaging Performance

Table 2: Quantitative In Vivo Imaging Metrics for [Probe Name] at 24h Post-Injection

Metric	ROI	Result (Mean ± SD, n=5)	Acceptance Criterion
Mean Tumor Signal (a.u.)	Tumor	1250 ± 180	N/A
Mean Background Signal (a.u.)	Muscle	210 ± 45	N/A
Tumor-to-Background Ratio (TBR)	Tumor/Muscle	6.0 ± 0.9	> 3.0
Signal-to-Noise Ratio (SNR)	Tumor vs. Muscle	23.1 ± 4.2	> 10
Time to Peak TBR (min)	--	120 ± 15	--

Title: Standardized In Vivo NIR-II Imaging Protocol

Conclusion

The implementation of robust NIR-II fluorescent probe protocols represents a transformative leap for non-invasive, deep-tissue biomarker detection. By mastering the foundational principles, meticulous methodologies, troubleshooting techniques, and validation benchmarks outlined in this guide, researchers can achieve unprecedented spatial resolution and imaging depth in complex biological systems. The comparative advantages over traditional NIR-I imaging are clear, offering a path toward more accurate disease modeling, drug efficacy assessment, and mechanistic studies in vivo. Future directions hinge on the development of brighter, more specific activatable probes, the standardization of imaging protocols across laboratories, and the critical translation of these techniques into clinical imaging modalities. As the field matures, NIR-II fluorescence is poised to become an indispensable tool in the pipeline from biomedical discovery to clinical diagnostics.